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Abstract 
 
The role of the central nervous system as a sanctuary site for HIV due to limited 
penetration of antiretroviral drugs, Dr Sam Nightingale. 
Introduction. HIV-associated neurocognitive disorders appear to remain common 
despite access to antiretroviral therapy (ART). Penetration of ART into the central 
nervous system (CNS) is highly variable between drugs and between individuals. 
Cerebrospinal fluid (CSF) concentrations of many antiretroviral medications fall 
below the minimum inhibitory concentration for wild type virus. HIV-1 RNA can be 
detected in the CSF at greater levels than in plasma (CSF/plasma discordance), 
however the clinical significance of this is unclear, and the degree of difference 
considered pathological varies. Whether the CNS can act as a sanctuary site leading to 
persistent HIV detection in plasma is not known.  
Methods. The PARTITION study recruited HIV positive adults from 13 UK clinical 
sites. Paired CSF and plasma was collected from patients undergoing LP for clinical 
indication (group A) and subjects with unexplained viraemia despite ART (group B). 
The study aimed to determine a) the prevalence of CSF/plasma discordance and 
factors associated with this occurrence, and b) the prevalence of HIV-1 RNA 
detection in CSF in those with HIV-1 RNA persistence in plasma. A sensitive assay 
detected HIV-1 RNA below 50 copies/ml in a subgroup and a cytometric bead array 
determined CSF biomarkers. A matrix of clinical features and CSF/plasma 
biomarkers was related to cognitive decline in subjects from the CHARTER study. 
Drug concentrations in CSF and plasma were measured by mass spectrometry assays 
and related to host genetic factors in subjects in the PARTITION study and a 
Vietnamese cohort with tuberculous meningitis.  
Results. CSF/plasma HIV discordance occurred in 13% of this cohort and was 
associated with nadir, but not current, CD4 cell count. CSF/plasma discordance 
occurred in 7 of 40 (18%) of subjects with ongoing viral detection in plasma vs. 0 of 
39 of those without. Residual HIV-1 RNA detection below 50 copies/ml was also 
associated with CSF HIV-1 RNA detection. Resistance associated HIV mutations 
were detected in CSF of subjects with CSF/plasma discordance. CSF/plasma 
discordance above 0.5log10 was associated with raised profiles of inflammatory CSF 
proteomic biomarkers compared to those without discordance. In the CHARTER 
cohort, cognitive decline over 18 months was associated with lower concentrations of 
CSF TNFa and plasma IGF1/2. CSF concentrations of efavirenz were associated with 
the CYP2B6 c.516G>T single nucleotide polymorphism. Efavirenz metabolites were 
mainly glucuronidated in CSF, were present at neurotoxic levels, and were related to 
degree of blood brain barrier permeability. Host genetic factors were did not relate to 
CSF DRV concentrations.  
Conclusions. CSF/plasma discordance is a frequent occurrence, likely related to 
processes established during advanced immunosuppression not fully reversed by 
ART. It is associated with CSF HIV resistance and raised CSF biomarkers, even at 
levels 0.5-1log10 which have been considered non-significant in some studies. 
Potentially neurotoxic CSF concentrations of efavirenz relate to host genetic factors.  	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1 Introduction  
1.1 Background 
Worldwide, approximately 34 million people are chronically infected with Human 
Immunodeficiency Virus (HIV) Type 1.1 In the UK over 90,000 people are infected, a 
quarter of whom are unaware of their diagnosis, and numbers continue to rise.2 
Antiretroviral therapy (ART) has revolutionised the treatment of HIV disease. Many 
now live healthily for many decades while on treatment and life expectancy for those 
with access to modern treatment now approaches that of uninfected cohorts.3 HIV 
enters the brain early in disease via migrating myeloid and lymphoid cells and 
establishes productive infection in perivascular macrophages and microglia. 
Restricted infection also occurs in astrocytes.4 Before the widespread use of ART, 
severe cognitive impairment was common affecting up to 50% of HIV infected 
individuals prior to death.5 In countries where ART has become widely available, the 
incidence of HIV-associated dementia (HAD) has dramatically declined along with 
other Acquired Immune Deficiency Syndrome (AIDS)-defining conditions.6 However 
in this era of more potent ART we continue to observe cognitive disorders. This has 
several possible underlying pathogenic mechanisms. Distribution of ART into the 
CNS can be poor, and ART concentrations in cerebrospinal fluid (CSF) fall below the 
inhibitory concentration for wild type virus for several drugs.7 This may have clinical 
consequences since some patients have detectable HIV ribonucleic acid (RNA) in the 
CSF even when it is undetectable in blood.8, 9 Other potential mechanisms include a 
legacy effect of CNS damage sustained prior to ART initiation, persistent immune 
and glial activation, ART neurotoxicity, and indirect effects of co-morbid conditions 
associated with HIV disease. The impact of this pathology may be evidenced by the 
finding that HIV-associated neurocognitive disorders (HAND), particularly milder 
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forms, persist in cohorts with access to treatment.10, 11 Some studies have suggested 
that as many as half of HIV-seropositive people in Europe and the USA may have 
cognitive impairment, which in many cases appears to be either asymptomatic or does 
not cause functional incapacity.12  
 
However, controversy exists in the field regarding several of these points. HAND 
prevalence estimates vary depending on the population and assessment methods.13-19 
Several guidelines now recommend screening for HAND, although the most 
appropriate populations to target and the best tools to use have not been determined 
for every clinical environment.20-22 The clinical significance of identifying 
asymptomatic impairment is not fully understood and there are uncertainties around 
the most suitable investigation and management of patients identified as cognitively 
impaired.23-25 Although persistently detectable HIV RNA in the CSF may herald 
progressive CNS damage, reports have not found that it consistently relates to 
cognitive functioning.26 Evidence suggests that some antiretroviral drugs are more 
effective in the CNS than others,7 but this conclusion depends on how effectiveness is 
estimated. Reports focusing on cognitive functioning have not consistently found 
differences between antiretrovirals, although methods vary substantially between 
studies and few randomised trials have been performed.27-29 This introduction chapter 
reviews these important clinical issues and provides approaches for resolving key 
issues of debate.  
 
1.2 Antiretroviral therapy 
Modern ART typically comprises a combination of at least three drugs.30 
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Nucleos(t)ide reverse transcriptase inhibitors (NRTIs) and non-nucleoside reverse 
transcriptase inhibitors (NNRTIs) inhibit reverse transcriptase. Reverse transcriptase 
(RT) is an HIV-specific DNA polymerase used to generate complimentary DNA from 
an RNA template. NRTIs were the first antiretroviral drugs to be discovered. Purine 
and pyrimidine nucleosides are required for proviral DNA elongation. NRTIs are 
structurally similar to DNA nucleoside bases. They become incorporated into the 
proviral DNA preventing incorporation into the host cell genome. NRTIs are prodrugs 
and undergo phosphorylation by intracellular kinases.31 Most antiretroviral regimens 
involve two NRTIs in combination to form an NRTI “backbone” (Table 1). NNRTIs 
non-competitively bind the p66 subunit at a site distant from the active site of the 
enzyme. This induces a conformational change in RT and alters the active site.  
NNRTIs are metabolised by the cytochrome P450 system via a number of specific 
isoenzymes (eg, CYP2B6, CYP2A6, CYP3A4, CYP2C9), and via uridine diphosphate 
glucuronosyltransferase (UGT) enzymes.32 Significant induction and inhibition occurs 
and can result in the potential for drug interactions (Table 2). 
 
Protease inhibitors (PIs) prevent cleavage of polypeptides to form functional subunits 
for viral capsid formation by competitively binding to HIV protease, a 99-amino-acid, 
aspartate protease that is responsible for maturation of HIV virus particles. PIs 
undergo significant first pass metabolism by CYP3A4 and 3A5. They are also 
substrates for the p-glycoprotein efflux transporter.33 This results in significant 
variability in PI pharmacokinetics between and within individuals. Ritonavir blocks 
intestinal and hepatic CYP3A metabolism. It is frequently co-administered at low-dose 
(100-200mg) with other PIs to improve pharmacokinetic availability and “boost” their 
effect, thus decreasing the variability in pharmacokinetics.33  
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Raltegravir is the most commonly used integrase inhibitor. Integrase inhibitors 
competitively inhibit the strand transfer reaction of proviral integration. This prevents 
or inhibits the binding of the pre-integration complex to host cell DNA, terminating 
the integration step of HIV replication.34  
 
HIV entry inhibitors include chemokine receptor antagonists and fusion inhibitors. 
The chemokine receptor 5 (CCR5) antagonist maraviroc selectively binds the CCR5 
co-receptor, preventing fusion of cell membranes following binding of HIV to the 
CD4 receptor. As such it is only effective for virus that uses the CCR5 co-receptor 
(termed CCR5 tropic virus) rather than CXCR4 tropic or dual/mixed tropic virus.35  
 
The fusion inhibitor enfuvirtide acts extracellularly to prevent the fusion of HIV to the 
CD4 cell by binding to the HR1 region of glycoprotein 41 (gp41) resulting in a 
conformational change.36 Enfuvirtide requires twice daily sub-cutaneous injection.  
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Table 1. Recommended first line antiretroviral therapy in UK 
[1] Abacavir is contraindicated if HLA-B*57:01 positive.  
[2] Nevirapine is contraindicated if baseline CD4 cell count is greater than 250/400 
cells/mL in women/men.  
[3] Use recommended only if baseline VL <100 000 copies/mL: rilpivirine as a third 
agent, abacavir and lamivudine as non-nucleoside reverse transcriptase inhibitor 
(NRTI) backbone. 
Adapted from the British HIV Association guidelines for the treatment of HIV-1-
positive adults with antiretroviral therapy 2012, updated Nov 2013.30  
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Table 2. Key pharmacokinetic parameters of the major antiretroviral drugs37 
BCRP, breast cancer resistance protein; MRP, multidrug resistance-associated 
protein; P-gp, P-glycoprotein; ADH, alcohol dehydrogenase; UGT, uridine 5'-
diphospho-glucuronosyltransferase; CYP, cytochrome P450; OATP, organic anion 
transporting polypeptides; na, not available. 
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1.3 Are some antiretroviral drugs more effective than others in the CNS?  
Evidence supports the concept that ART generally protects the CNS: current regimens 
suppress CSF HIV RNA in the majority of adherent patients, have reduced the 
incidence of HAD, and have improved histopathological findings in brain tissue of 
patients dying with HIV disease.38, 39 A central question is whether some ART drugs 
are more effective in the brain than others.   
 
Several drug characteristics influence the distribution of ART into the CNS including 
molecular weight, protein binding, fat solubility, and influx/efflux transporters on 
brain endothelium.40 As a result there is a wide range of CSF ART concentrations 
across different ART classes and individual drugs within a class. A hierarchy of drug 
distribution into the CNS has been proposed based on drug chemical properties, 
pharmacokinetics, and effectiveness in clinical studies.7 The CNS Penetration 
Effectiveness (CPE) score assigns each drug an integer between one and four (Table 
3), with one indicating below average estimated effectiveness and four indicating 
much above average estimated effectiveness. The CPE score is the sum of all 
antiretrovirals in a regimen. The score was devised as a research tool but has been 
used by some to guide prescribing in those with neurological complications of HIV. 
However the score has several limitations, as described below, and the benefits of its 
use in the clinic are unproven. A consensus report from the Mind Exchange Working 
Group, a group of 66 specialists from 30 countries, suggests that for patients with 
persistent or worsening neurocognitive impairment and detectable CSF HIV RNA, 
modifying treatment according to CPE score may be an option when other factors 
(e.g., poor adherence, virological resistance and comorbidities) have been 
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considered.20 The CPE score is not part of the European AIDS Clinical Society 
(EACS) guidelines for the treatment of cognitive impairment – these guidelines refer 
instead to use of “CNS-active” ART; an approach to categorisation that has some 
overlap with drugs that are “above average” using the CPE approach.22 The current 
British HIV Association (BHIVA) guidelines expressly advise against use of the CPE 
method to guide prescribing.41  
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 4 3 2 1 
NRTIs Zidovudine Abacavir Didanosine Tenofovir 
 Emtricitabine Lamivudine Zalcitabine 
  Zalcitabine  
  Stavudine  
NNRTIs Nevirapine Delavirdine Etravirine  
 Efavirenz   
PIs Indinavir-r Darunavir-r Atazanavir-r Nelfinavir 
 Fosamprenavir-r Atazanavir Ritonavir 
 Indinavir Fosamprenavir Saquinavir-r 
 Lopinavir-r  Saquinavir 
   Tipranavir-r 
Fusion/Entry 
Inhibitors 
 
Maraviroc 
 
Enfuvirtide 
Integrase 
Inhibitors 
 
Raltegravir 
  
4 = much above average, 3 = above average, 2 = average, 1 = below average; NNRTIs = non 
nucleoside reverse transcriptase inhibitors; NRTIs = nucleoside reverse transcriptase inhibitors; PIs = 
protease inhibitors 
   
Table 3. CNS Penetration Effectiveness (CPE) 2010 ranking scale.7  
CPE score is sum of the individual scores of all drugs in regime. 
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In cohort studies, the CPE score has been statistically significantly associated with 
CSF HIV RNA; the greater the regimen CPE score the lower the proportion of 
patients with detectable CSF HIV RNA.24, 42 To date the evidence linking higher CPE 
scores to improved cognitive performance has been mixed.27-29 A systematic review 
using rigorous methods concluded that antiretrovirals with higher estimated CNS 
penetration were effective in improving cognitive function and decreasing CSF HIV 
RNA levels, but only two of the included studies were adequately statistically 
powered and all were observational.43 The only randomised trial to date of better CNS 
penetrating ART for treatment of HAND used a “CNS-targeting” approach that took 
CPE into account when selecting a new ART regimen. This trial found no difference 
in the neurocognitive outcome 16 weeks after the ART change, although it was 
underpowered, enrolling only 49 of the planned 120 subjects.44 A planned subgroup 
analysis of subjects who entered the trial with suppressed plasma HIV RNA did 
identify a trend towards neurocognitive benefit in the CNS-targeted arm. Subjects in 
the CNS-targeted arm, however, also trended towards poorer plasma virologic 
suppression at 16 weeks, supporting the idea that prescribing solely on the basis of 
estimates of CNS penetration, rather than proven efficacy, may lead to unacceptable 
clinical outcomes.  
 
One theory is that antiretrovirals with the lowest CNS concentrations, as estimated by 
CSF drug levels or CPE score, are more likely to develop resistance mutations in the 
CNS than in the periphery. The findings in the literature to date are mixed,45, 46 
although a high viral genetic diversity suggesting autonomous replication in the CNS 
	   32	  
has been associated with low CPE score.47 An adjusted CPE score has been proposed, 
taking into account virological resistance mutations in the CSF.48  
 
One criticism is that the CPE score is heavily reliant on pharmacokinetic data from 
CSF, not brain tissue itself. Although CSF is commonly used as a surrogate for brain 
events, drug concentrations in CSF may not accurately reflect drug concentrations in 
brain tissue. Drug concentrations in CSF and brain tissue can differ for several 
reasons, including the differing characteristics of the blood-brain and blood-CSF 
barriers.49 Indeed drug concentrations can differ between the brain tissue and CSF,50 
as well as between different brain regions.51 While currently impossible to ascertain in 
living people, the concentration that may best predict ART effectiveness in the brain 
is that within perivascular macrophages, a critical target cell of HIV in the brain.4 
NRTIs and NNRTIs are not generally effective in chronically infected macrophages 
and the 90% inhibitory concentration (IC90) at which PIs inhibit replication is higher 
in macrophages than in T lymphocytes.52, 53 
 
Direct comparisons of individual antiretroviral drugs is challenging since this requires 
administration of monotherapy, a practice that is uncommon in most clinics. In a 1993 
report, zidovudine showed efficacy against HAD.54 Since then, few drugs have been 
assessed in isolation in controlled trials. Recently simplifying maintenance treatment 
to a single PI has been investigated as an approach that might reduce toxicity while 
maintaining full viral suppression. Concern exists that PI monotherapy may not 
control HIV replication in the brain since PI drug concentrations in the CSF can be 
low, perhaps because many are substrates for drug efflux transporters.55 Despite this 
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concern, PI monotherapy was not associated with cognitive impairment when 
compared with triple drug ART in a recent observational study of 191 subjects.56  
 
1.3.1 Neurotoxicity 
Evidence is mounting that at least some modern antiretroviral drugs can cause 
neurotoxicity.25, 57, 58 The relationship between the drug concentration required to 
inhibit HIV replication in the CNS and the concentration required to cause 
neurotoxicity likely differs by drug. As such it does not necessarily follow that the 
drugs that have the highest distribution into the CNS will also be the most neurotoxic. 
The ultimate goal is to identify which drugs best balance efficacy and toxicity, 
maintaining concentrations in the so-called “therapeutic window”.  
 
In addition to direct injury of neurons, ART may also indirectly alter brain 
functioning via immune, glial or endothelial effects. One potential mechanism is a 
low-grade immune reconstitution inflammatory syndrome (IRIS) in the absence of 
underlying lesion leading to chronic lymphocyte activation and persistent 
inflammation in the CNS in those on ART.26, 59, 60 Such events present challenges for 
neurocognitive recovery and eradication of HIV from the CNS. 
 
1.4 What is the clinical significance of HIV RNA detection in the CSF? 
Systemic HIV replication is a risk factor for cognitive impairment and HIV RNA in 
blood has been independently associated with cognitive impairment.12 Cognition 
typically improves following virological control with effective ART, even if the 
subject was not functionally impaired at baseline.61 This has been elegantly 
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demonstrated in animals: Rhesus macaques experimentally infected with simian 
immunodeficiency virus (SIV) had only 70% the locomotor activity of those 
uninfected. Following effective ART, locomotor activity returned to pre-infection 
levels.62  
 
Only 19% of all HIV infected individuals in the US are estimated to achieve 
suppression of HIV in blood;63 only 80% are aware of their diagnosis and fewer still 
have been linked to HIV care, stay in HIV care, receive ART, and are able to adhere 
to their treatment. While aviraemic patients taking ART may represent a minority of 
the total HIV-infected population, the prevalence of HAND in this population is 
substantially lower than in those who are taking either no, or ineffective, ART. A UK 
cross-sectional study of 100 asymptomatic subjects, all aviraemic on effective ART, 
found cognitive impairment in just 19% overall, similar to that expected in an HIV 
negative population.64, 65  
 
Plasma HIV RNA levels can strongly correlate with those in CSF. Whether HIV 
replication within or outside the nervous system, or both, leads to CNS injury remains 
unknown.  
 
1.4.1 CSF/plasma discordance  
Modern ART can control systemic viraemia well but concern has arisen that it may 
not fully control HIV replication in the CNS where drug levels can be much lower. 
Markers of neuroinflammation and neurodegeneration remain raised in the CSF of 
ART treated patients. Such markers include beta-2-microglobulin (a marker of 
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cytotoxic T-lymphocytes in the CNS), neopterin (a marker of macrophage/monocyte 
activation), S100B (a marker of astrocytosis), neurofilament light chain (a major 
structural protein of neurons) and a number of pro-inflammatory modulators including 
interleukins, interferons, chemokines and tumor necrosis family proteins.26 
Neuroimaging studies of ART treated patients have shown reduced brain volume, 
changes in brain metabolites on magnetic resonance spectroscopy and reduced white 
matter structural integrity on diffusion tensor imaging.66 Neuropathologic changes 
also persist in ART treated patients and correlate to cognitive dysfunction.67 
 
CSF/plasma discordance describes HIV RNA at higher levels in CSF than in plasma. 
There is currently no consensus on the degree of discordance between CSF and 
plasma HIV-1 RNA that should be considered clinically significant. Some studies 
have defined discordance as CSF HIV-1 RNA 1log10 greater than the corresponding 
plasma sample,68 while others have used a lower cut off of 0.5log10.8 In those with 
unquantifiable HIV-1 RNA in plasma (typically <50 copies/ml) some studies have 
described the detection of CSF virus at any level above 50 copies/ml (termed “CSF 
viral escape”),9 while others have excluded those with CSF HIV-1 RNA below 200 
copies/ml.8, 68  
 
Sensitive testing can now detect HIV-1 RNA below the traditional threshold of 50 
copies/ml. A proportion of patients have CSF/plasma discordance detected on these 
assays that would not otherwise be classified as discordant if tested with standard 
assays.39, 69 The source and significance of CSF/plasma discordance at this low level 
remains controversial.20, 70 Sensitive testing is currently a research tool. However 
assays with a lower limit of quantification of 20 copies/ml are now being used 
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routinely in many clinical centres and consequently CSF/plasma discordance below 
50 copies/ml is an increasingly recognised phenomenon in clinical practice.  
 
Depending on the definition used, CSF/plasma discordance occurs in approximately 
10% of individuals undergoing lumbar puncture in clinical practice.8, 9, 39, 71 Studies in 
which a lumbar puncture was performed solely for research purposes in asymptomatic 
individuals found the prevalence of CNS/plasma discordance to be lower.9, 39 
Although common, the degree to which CSF/plasma discordance leads to CNS injury 
and HAND remains uncertain. CSF/plasma discordance has been associated with a 
number of fulminant syndromes in case series including reduced conscious level, 
dementia and status epilepticus, but these appear to be uncommon in clinical 
practice.48, 68 In untreated subjects in the pre-ART era, greater levels of HIV RNA in 
the CSF were associated with HAD,72-75 however the association between CSF HIV 
RNA and cognitive function in treated subjects in the era of potent ART is less 
clear.26, 73, 76   
 
CSF analysis from the large US National Institute of Mental Health-funded CNS HIV 
AntiRetroviral Therapy Effects Research (CHARTER) cross-sectional cohort study 
showed that the absolute level of CSF HIV RNA was not related to cognitive 
performance but the presence of discordant virus was.39 However this association was 
present using an assay that can detect HIV RNA at 2 copies/ml, a standard that is 
much more sensitive than currently used in clinical practice. Other studies have 
demonstrated no association between CSF HIV RNA levels and cognitive 
performance but few have used such sensitive assays.77 The Mind Exchange 
consensus report recommends using a sensitive assay to quantify HIV RNA to 1-2.5 
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copies/mL in those with HIV RNA less than 50 copies/ml in both CSF and plasma, 
who have cognitive impairment confirmed on neuropsychological testing without 
alternative explanation.20 This recommendation is based on two reports at 
international conferences that have not yet been published in peer-reviewed 
journals;39, 69 the merits of this approach require further investigation.  
 
One explanation for the weakness of association between CSF HIV RNA and 
cognitive functioning is that CSF HIV RNA levels are only an imperfect proxy for 
HIV replication in brain tissue. While regional brain levels correlate to some extent 
with CSF levels, this correlation is not always strong, hence levels of HIV RNA in the 
CSF may not always be an accurate surrogate for production of HIV virions (and viral 
proteins) within the brain.78, 79 Another explanation relates to the pathogenesis of 
cognitive impairment in HIV; if this is a result of immune dysregulation rather than 
virus-related cytopathy, then CSF HIV RNA may not be the most useful biomarker. 
In fact, in large cohorts, cognitive impairment appears to correlate more strongly with 
severity of prior immunosuppression than with CSF HIV RNA.80 One cohort study 
showed that 21% of 203 patients with AIDS progressed to HAD despite being 
aviraemic with undetectable HIV RNA in CSF.77 Based on this and other published 
findings, a combination of biomarkers reflecting neuronal injury and glial or immune 
activation in combination with CSF HIV RNA may be more useful than CSF HIV 
RNA alone.26, 81 However, the clinical validity, reproducibility, and cost-effectiveness 
of these biomarkers have not been evaluated. 
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1.4.2 Can antiretroviral drug resistance develop in the CNS? 
If HIV can continue to replicate in the CNS in the presence of sub-therapeutic levels 
of ART, drug resistance could develop. Studies have found mutations conferring 
resistance to several classes of ART in the CSF when they were not present in 
blood.82-84 In two separate case series of patients with new onset neurocognitive 
impairment or other neurological symptoms, and CSF/plasma discordance, the 
majority had resistance-associated mutations detected in CSF.48, 68 Altering ART 
based on drug resistance mutations in CSF led to clinical improvement and decrease 
in CSF HIV RNA in both series.  
 
In addition to differences in the drug resistance patterns between CSF and plasma, 
HIV may differ in terms of pathogenicity, tropism, and co-receptor use. These 
differences may be due to adaptation of the virus to CNS target cells, or to differences 
in exposure to ART in the CNS compartment.85, 86 The degree of 
compartmentalisation is associated with duration of infection, past immune 
suppression, and risk of HAD. Of note, indicators of compartmentalisation do not 
differ between those with mildly impaired cognitive function and unimpaired patients, 
supporting the hypothesis that the impact of HIV genetics on neuropathogenesis 
differs between milder and more severe forms of HAND.87, 88 One reason may be that 
the most severe form of HAND, HAD, is associated with the most advanced 
immunosuppression, which may allow increased viral replication and accelerate viral 
evolution in the CNS.  
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Although drug resistance testing of CSF is not currently recommended for the routine 
management of asymptomatic patients, it may be useful in those with neurocognitive 
impairment and other neurological disorders and forms part of the current EACS, 
BHIVA and Mind Exchange guidelines.20, 22, 41 What is not clear, however, are the 
implications of viral resistance in the CNS for HIV treatment failure systemically. 
The goal of antiretroviral therapy (ART) is sustained suppression of HIV-1 RNA in 
plasma, commonly interpreted as a viral load <50 copies/ml.41 Some ART treated 
individuals do not maintain viral suppression below this level; HIV-1 RNA above 50 
copies/ml may be intermittent “blips” or persistent low-level viraemia. HIV-1 RNA 
levels between 50 and 400 copies/ml have not been associated with long-term 
virological failure in most studies,89 however it is not known whether some cases of 
HIV-1 detection at this level may represent ongoing replication in sanctuary sites such 
as the brain. It is not clear whether such patients should be offered a lumbar puncture 
or have changes made to ART based on estimated CNS penetration; indeed clinical 
practice varies in this regard. More work is needed to determine the clinical 
applications of CSF HIV resistance testing and the implications of drug resistant 
mutations in the CSF for systemic HIV control. 
 
1.5 How common are HIV-associated neurocognitive neurocognitive 
disorders in the antiretroviral era?  
HAND is defined by the widely used research classification, the Frascati criteria 
(Figure 1). The Frascati criteria divide HAND into asymptomatic neurocognitive 
impairment (ANI), mild neurocognitive disorder (MND) and HIV-associated 
dementia (HAD). CNS problems in HIV infection remain a major public health 
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problem in resource poor settings, however in this section I will focus on the problem 
of HAND in populations with access to potent ART. Cross-sectional studies indicate 
that HAND remains common in industrialised nations in the era of widespread ART 
availability (Figure 2). The CHARTER study reported cognitive impairment in 53% 
of 1555 HIV-seropositive patients.12 This cohort was designed to reflect the clinic 
population and, as such, it includes all causes of cognitive impairment occurring in 
people with HIV. Among the 843 people of this cohort who had minimal 
neuropsychiatric confounding conditions (i.e., no conditions, other than HIV disease 
accounting for reduced neurocognitive functioning), 40% met criteria for cognitive 
impairment. Multiple other studies estimate HAND prevalence between 20 and 
50%,13-19 with some finding that HAND could occur in as much as 69% of the HIV-
seropositive population despite adequate ART.27 This wide range of prevalence 
estimates has resulted in uncertainty about the prevalence that best describes cognitive 
impairment due to HIV pathology in populations with access to ART. 
 
 
 
 
 
 
 
HIV-associated  
neurocognitive disorders 
(HAND) 
HIV-associated  
dementia 
(HAD) 
 
Marked cognitive impairment 
[3] which produces marked 
interference with daily 
functioning 
Asymptomatic neuro- 
cognitive impairment 
(ANI) 
 
Mild cognitive impairment [1] 
which does not interfere with 
daily functioning 	  
Mild neurocognitive  
disorder 
(MND) 
 
Mild cognitive impairment 
[1] that interferes with 
daily functioning [2]   
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Figure 1. Summary of Frascati criteria for HIV-associated neurocognitive 
disorders.90 
[1] Performance on neuropsychological tests of at least 1 standard deviation below 
age-education corrected norms in at least two cognitive domains. The assessment 
must survey at least the following domains, if possible with at least two test measures 
per domain: verbal/language; attention/working memory; abstraction/executive; 
memory (learning; recall); speed of information processing; sensory-perceptual, 
motor skills. Impairment must be acquired, cannot be explained by other 
comorbidities, and there is no evidence of delirium or preexisting cause.  
[2] Daily functioning can be formally assessed by Lawton & Brody’s modified 
Activities of Daily Living scale and/or the Patient’s Assessment of Own Functioning 
Inventory.91, 92 
[3] Performance on neuropsychological tests of at least 2 standard deviations below 
demographically corrected mean for norms in at least two cognitive domains. 
Typically the impairment is in multiple domains, especially in learning of new 
information, slowed information processing, and defective attention/concentration. 
The pattern of cognitive impairment does not meet criteria for delirium and there is 
no evidence of another, preexisting cause for the dementia. 
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Figure 2. Changes in the US prevalence of HAND in the era before (HNRC study, 
n=678) and after (CHARTER study, n=843) the widespread use of potent ART.10-12  
ANI, asymptomatic neurocognitive impairment; MND, Mild neurocognitive 
impairment; HAD, HIV-associated dementia; HAART, highly active antiretroviral 
therapy.  
1.5.1 Co-morbid conditions also influence neurocognitive functioning 
There are multiple factors that may predispose to cognitive impairment in an HIV 
infected individual; these are detailed in Figure 3. The extent to which each factor 
contributes to the prevalence of cognitive impairment in different populations is 
unclear. Although many co-morbid factors are linked to reduced cognitive 
functioning, strictly speaking they do not cause HAND as the Frascati criteria state 
the diagnosis is only possible if cognitive impairment is not explained by co-morbid 
conditions (Figure 1). Considering co-morbid conditions and HIV risk factors is 
important in studies of HAND and the assessment of HIV-seropositive patients with 
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cognitive impairment. Some, such as low nadir CD4+ T-cell count, are potentially 
preventable risk factors for HAND, while others, such as depression and systemic 
HIV replication may be amenable to treatment.  
 
Many such cofactors were evident in the CHARTER cohort; those with cognitive 
impairment were more likely to have hepatitis C co-infection or AIDS, had a lower 
nadir CD4+ T-cell count, had more comorbidities, were more likely to have substance 
abuse or be depressed, and were older and more poorly educated than those without 
cognitive impairment. Overall 52% had cognitive impairment, however this varied 
from 83% in those with severe neuropsychiatric comorbidities to 40% in those with 
minimal neuropsychiatric co-morbidities. Even in the latter group with the least 
comorbidities, 71% had a diagnosis of lifetime substance use (16% had recent use 
demonstrated by positive breathalyzer or urine drug screen), 16% had current 
depression or psychotic disorder, 60% had AIDS, and 60% had detectable HIV RNA 
in plasma (not all were taking ART).12 This diverse population might generalise well 
to the HIV clinical population in the U.S. but not to the ideal patient who is taking 
long-term suppressive ART that was begun at an early stage of disease and who has 
good immune recovery. Differences in the prevalence and severity of these factors 
explains some of the observed variation in estimates of HAND prevalence between 
studies. Based on these findings, multiple conditions should be considered in the 
assessment of HIV-seropositive patients with cognitive impairment; a careful clinical 
assessment is essential to identify the most important.  
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Figure 3. Overview of proposed pathological mechanisms underlying HIV-
associated neurocognitive disorders 
Advanced immunosuppression prior to treatment initiation, as estimated by the nadir 
CD4+ T lymphocyte count, is strongly associated with cognitive impairment [1].12, 16 
This may be due to a degree of irreversibility in pre-treatment CNS injury, termed a 
“legacy effect”. Alternatively there may a process of immune or glial activation set up 
during advanced immunosuppression which persists following treatment and immune 
recovery [3].4 In some patients variation in CNS distribution of ART may be 
important; suboptimal levels [4] may lead to failure to suppress HIV replication in 
the CNS [5].24, 42 CNS HIV replication may also be driven by systemic HIV control 
[6].12 Direct neurotoxicity occurs from the HIV virus and its proteins, such as the 
envelope glycoprotein gp120 and the regulatory protein Tat [7], which may be 
increased for different HIV clades. Chronic sustained immune activation in the CNS 
leads to the production of neurotoxic products such as nitric oxide, arachidonic acid 
and pro-inflammatory cytokines [8].93 Some antiretroviral drugs may be directly 
neurotoxic [9].25 Immune reconstitution inflammatory syndrome (IRIS) is an 
alternative mechanism by which antiretroviral therapy may damage the CNS; an 
insidious low-grade immune IRIS in the absence of pathogens other than HIV may 
lead to chronic lymphocyte activation and persistent inflammation in the CNS [10].26, 
59, 60 This may be more severe in those with advanced immunosuppression at 
treatment initiation [1].12, 16  Cerebrovascular disease [11] can result from the 
metabolic and systemic effects of HIV disease [6] and its treatment [12] on 
endothelial function and cardiovascular risk factors.94, 95 These mechanisms may 
become increasingly important as the HIV-seropositive population ages [16], and the 
CNS can be affected by so called “premature aging” associated with HIV infection. 
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Hepatitis C infection [13] is associated with cognitive dysfunction independently of 
HIV,96 and this effect is compounded by HIV disease. HIV and hepatitis C co-infected 
patients may be almost twice as likely to have cognitive impairment as HIV-
seropositive individuals without HCV infection.97, 98 The use of psychoactive drugs 
[14], in particular methamphetamine, has a deleterious effect on cognition which is 
more pronounced in combination with HIV infection.99, 100  
Host genetic factors [15], in particular the apolipoprotein E4 allele, have been 
associated with HAD, but the association with milder impairment is inconsistent.101, 
102  Cognitive changes related to ageing [16] may be compounded by HIV 
infection,103 and low educational level [17] can contribute to poor cognitive 
performance. Mood disorders [18] may masquerade as, or be caused by, cognitive 
impairment.104  
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1.5.2 Prevalence estimates vary with demographic characteristics 
HAND is defined by deviation from normative neuropsychological testing data that 
are derived from a control population that is matched to the target population for at 
least age and education (referred to as “norms”, see Figure 1). These criteria therefore 
depend on how accurately the control population reflects the tested population. The 
socioeconomic, ethnic, and educational diversity of the typical HIV population in 
Europe and the North America makes using appropriately matched control data 
essential for determining cognitive impairment. Demographic variation can affect the 
proportion classified as impaired, as evidenced by clinical trials that did not use 
appropriate normative data. For example variation in cognitive status has been 
demonstrated between countries studied,105 and between ethnic groups within a 
country.106 Although these differences could potentially be due to disease-related 
factors (e.g., HIV clade), other causes include the educational, cultural, and social 
differences that vary by geographical region and clinical settings.107  
 
Perhaps the best opportunity to study a representative control group was provided by 
a cohort of Chinese plasma donors.14, 108 Farmers in a rural area of China 
supplemented their income by donating plasma to a local laboratory. Several hundred 
became infected with HIV due to the use of unsterilised needles. This tragic situation 
provided a rare opportunity to study a well-matched control group by comparing 
infected subjects with those attending the same clinic who did not become infected. 
Cognitive assessment of this population demonstrated impairment in 34-39% of 203 
HIV-seropositive subjects (depending on hepatitis C co-infection) compared to 13% 
of 198 subjects without HIV.14 When followed over one year, 28% of those with HIV 
deteriorated compared to only 5% of those without HIV.108 Of note however, the HIV 
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population in this study was not ideal: less than half of patients who took ART had 
undetectable plasma HIV RNA, 93% had hepatitis C co-infection, and the majority 
had previously progressed to advanced immune suppression or AIDS, which are 
known risk factors for HAND.  
 
Studies using comprehensive neuropsychological testing, stringent criteria for the 
definition of HAND and well-matched control data, have found HAND prevalence to 
be high.12 However, the challenge is generating the most appropriate normative data 
for each clinical setting. 
 
1.5.3 Possible diagnostic overestimation: The role of the HAND definition  
Debate about the current HAND classification approach is ongoing. Concerns have 
been raised that this approach will overestimate HAND prevalence by falsely 
classifying a proportion of the target population as impaired solely as a consequence 
of the method, not because they have a medical illness (i.e., they have a ‘false 
positive’ diagnosis). A purely statistics-focused approach using the criterion of two 
impaired tests per domain will identify 8-13% of the normative population – and 
therefore the target population as well – as having impaired performance.109 Some 
studies have used the less conservative criterion of one impaired test per domain;12 in 
this situation the ‘false positive’ frequency rises to 16-21%. The former figure is 
considered by some to be more accurate than the latter and is similar to the 14% of 
HIV seronegative controls classified as impaired in the normative population of some 
studies.90 Proponents of this reasoning raise the concern that adoption of these criteria 
into clinical practice will result in misdiagnosing approximately 14% of patients as 
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having HAND, which could lead to costly and potentially unsafe clinical interventions 
as well as anxiety and stigma among misdiagnosed patients. The counterargument is 
based on at least two facts: worse performance on neuropsychological testing reflects 
worse functioning regardless of the population (HIV-seropositive or negative) and 
HAND is not diagnosed solely on the basis of neuropsychological testing results. HIV 
negative populations that are evaluated as normative ‘controls’ have a spectrum of 
functioning that ranges from much worse-than-average to much better-than-average. 
The individuals in the normative population who have the worst test performance are, 
by definition, the lowest functioning. Thus, individuals in the target population who 
perform at a level similar to the lowest functioning normative controls are themselves 
also low functioning. Requiring that individuals perform poorly in at least two 
cognitive abilities (as the Frascati criteria do) is intended, in part, to reduce the risk of 
misdiagnosis. Importantly, HAND diagnosis does not depend solely on cognitive 
testing but includes additional criteria: the impairment must not precede HIV 
transmission and severely confounding diagnoses (e.g., psychosis and active 
recreational drug use) and delirium must be absent at the time of diagnosis. 
Diagnostic confidence is further strengthened when the impaired performance is new, 
i.e. a decline has occurred.  
 
In summary, some experts are concerned that the current approach to diagnosing 
impaired neuropsychological test performance will lead to false positive diagnoses of 
HAND with attendant financial and emotional costs. Others point out that HAND 
diagnosis is not based solely on neuropsychological test results and that below-
average performance on properly normed neuropsychological tests is reason for 
concern and further evaluation regardless of the cause.  
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1.6 What is the clinical significance of asymptomatic neurocognitive 
impairment; should the HIV-seropositive population be screened for 
cognitive difficulties?  
People with ANI have poor performance on cognitive testing but by definition do not 
have symptoms or diminished daily functioning.90 Estimates of prevalence vary but 
ANI may occur in 33% to 60% of HIV-seropositive people despite ART.12, 27 
Although ANI is a research classification, both symptomatic and asymptomatic 
cognitive impairment have been associated with poorer quality of life, unemployment, 
worse medication adherence and lower driving ability.110 Even mild cognitive 
impairment has been associated with neuropathologic evidence of HIV-encephalitis in 
some patients.67 In the CHARTER cohort, patients with ANI were at significantly 
higher risk of progressing to symptomatic or functional impairment (termed mild 
neurocognitive disorder or MND) than those with normal cognitive function.111 This 
has led to questions about the value of routine screening for ANI in the HIV-
seropositive population.  
 
The Mind Exchange consensus report advocates screening for HAND in all patients, 
regardless of symptoms or risk factors, using sensitive screening tools.20 It suggests 
this be done early in disease and every 6-24 months thereafter. BHIVA also state that 
screening should be performed annually – however do not give details of which 
methods should be used or which populations should be targeted.21 Guidance from 
EACS recommends restricting formal neuropsychological testing to patients who are 
symptomatic on a screening questionnaire.22 
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Several important issues should be considered regarding screening for ANI. For a 
screening test to be clinically useful the disease must have a well-defined early stage 
that would progress to a more severe stage without intervention. An effective 
intervention should be available and the distress and subsequent investigation of a 
positive screening result must be outweighed by the benefit of early treatment.112 
Since no effective therapy for ANI other than ART has yet been identified, the 
benefits of screening asymptomatic patients who have normal daily functioning and 
are already taking suppressive ART are debatable, particularly since no single 
screening method appears to be adequately sensitive and specific for ANI in all 
clinical settings. In many cases ANI is not progressive; for instance around half of 
people with any form of HAND fluctuate in cognitive functioning over time, with 
improvement from HAND to an unimpaired classification occurring as frequently as 
deterioration.15 This variation may be due to true fluctuations in the pathological 
process, perhaps reflecting varying degrees of HIV replication in the CNS, or may 
reflect limitations in neurocognitive testing methods. Importantly, whether the poorer 
outcomes reported in those classified as ANI are driven primarily by HIV, by 
comorbid disorders, or both is unclear.  
 
There may be some merit in identifying patients who have early impairment so that 
risk factors can be controlled, treatment adjusted and progression monitored. 
Changing ART based on distribution into the CNS, efficacy in monocytes, or 
neurotoxicity has been posited as a treatment for ANI, but no randomised clinical 
trials have yet clearly supported these or other interventions, such as exercise or 
cognitive rehabilitation. As a result no strong consensus exists on the best course of 
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action for patients who are taking adequately suppressive ART and are identified as 
having ANI, and there is no widely accepted framework for changing ART based on 
differences between drugs in estimated effectiveness or toxicity in the CNS.23-25 A 
remaining important consideration is the impact of the screening process on patients; 
informing an asymptomatic individual that they have cognitive impairment could 
cause emotional distress. For these and other reasons, routine cognitive screening for 
ANI has not yet been widely adopted in the clinic.   
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HIV-Associated Neurocognitive Disorders are Common in the Antiretroviral Era. 
For Against 
Multiple, well powered, observational studies have demonstrated 
cognitive impairment in up to 60% of populations with access to 
antiretroviral therapy. Most subjects typically have asymptomatic 
disease.12-19, 27  
Approximately 15% of normative populations will be classified as 
impaired. Functioning at the lower end of the normative 
population may be concerning but HIV-related neuropathology is 
not necessarily the cause.  
Some studies that found high prevalence used a thorough 
neurocognitive evaluation and matched control data to key 
demographic variables.12  
Prevalence estimates depend on use of appropriate normative data 
(norms). Most studies did not use norms appropriate to all 
demographic groups in their cohort. 
Prevalence remains high in sub-populations with few 
neuropsychiatric co-morbidities.12 
Prevalence estimates derive from mixed populations who have 
other conditions that can affect cognition. Prevalence has been 
similar to HIV uninfected controls in ideal HIV patients who are 
taking durably suppressive ART and who do not have these other 
conditions.64, 65 
 
People with HIV Should be Screened for Asymptomatic Neurocognitive Impairment.  
For Against 
As ANI is typically more common than MND or HAD, most 
impairment would go unrecognised without screening.  
No ANI screening tools perform well in all clinical settings. 
ANI has been associated with poorer quality of life, worse 
medication adherence, and unemployment.110  
There is no consensus on the management of ANI. Screening 
could lead to diagnostic procedures that may be unnecessary, 
costly and invasive. 
ANI may be associated with increased risk for progressive 
neurocognitive disease.111 
Worse outcomes in ANI may be related to associated 
comorbidities in this group. 
A negative screen may reassure patients who are aware of the high 
prevalence of ANI. 
A positive screen may upset patients 
 Screening for ANI uses clinical resources which are limited. 
 
HIV RNA in CSF is a Useful Clinical Tool in the Assessment of HIV Patients.  
For Against 
In the era before antiretroviral therapy, higher HIV RNA in CSF 
was associated with HAD in people who had advanced immune 
suppression.72-75 
In people successfully treated with ART, cognitive impairment 
may be caused by ongoing inflammation within the CNS and/or 
comorbidities, rather than ongoing HIV replication. 
Case series have linked improvements in CNS symptoms to 
declines in HIV RNA in CSF.48, 68 
HIV RNA levels in CSF may not accurately reflect HIV 
replication in brain parenchyma. 
One antiretroviral era study found that people with greater HIV 
RNA in CSF than in blood were more likely to have 
neurocognitive impairment.73 
Most studies have failed to show an association between HIV 
RNA in CSF and neurocognitive status in the antiretroviral 
therapy era. 
Persistent HIV RNA in CSF during antiretroviral therapy may 
increase the risk of antiretroviral resistance and virologic failure.82-
84 
No longitudinal studies have demonstrated that people who have 
CSF/plasma discordance are more likely to develop antiretroviral 
resistance or progress to virologic failure. 
 
Some Antiretroviral Drugs are More Effective in the CNS than Others.  
For Against 
Concentrations of some antiretrovirals in CSF do not exceed the 
inhibitory concentration for wild-type HIV.   
Using routine HIV RNA assays, CSF/plasma discordance is 
uncommon during therapy with any antiretroviral combination.12 
Drugs with poorer estimated CNS effectiveness have been 
associated with higher HIV RNA in CSF.24   
Some observational studies have not found an association between 
drugs with better estimated CNS effectiveness and neurocognitive 
functioning.12, 27-29, 113 
Some studies have identified that drugs with higher estimated 
CNS effectiveness are associated with better neurocognitive 
performance.43 Studies have also identified that some 
antiretrovirals are neurotoxic.25 
Estimates of CNS effectiveness are largely based on antiretroviral 
pharmacokinetics in CSF, which may not accurately reflect 
antiretroviral pharmacokinetics in infected glial cells or brain 
macrophages. 
Some observational studies have reported HIV RNA declines in 
CSF and neurocognitive improvement following ART changes 
based on estimated CNS effectiveness.62, 63 
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Table 4. Summary of arguments for and against clinical statements associated with 
controversy in the field of HIV-associated neurocognitive disorders.  
HIV, human immunodeficiency virus; ART, antiretroviral therapy; ANI, asymptomatic 
neurocognitive impairment; MND, mild neurocognitive disorder; HAD, HIV-
associated dementia; RNA, ribonucleic acid; CSF, cerebrospinal fluid; CNS, central 
nervous system.  
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1.7 Conclusions and future directions  
A summary of the arguments surrounding the key areas of controversy in the field of 
HIV-associated neurocognitive disorders is given in Table 4.  	  
1.7.1 ART effectiveness in the CNS  
Large, prospective, well-stratified, randomised trials are required to determine the 
association between cognitive performance and the CNS distribution of different ART 
regimens. Cross-sectional studies may no longer be reliable since at least some 
prescribers may tend to select more “CNS active” regimens for their patients who 
have evidence of CNS problems.114 Given the number of ART combinations in use 
and the length of follow up required, evaluating each regimen in this manner is a 
major undertaking.  
 
One alternative strategy is to monitor improvements in cognitive functioning 
following ART initiation. In most individuals there is improvement in cognitive 
function following commencement of effective ART,115, 116 which is detectable as 
early as three months,117 and may continue beyond a year.118 This effect has been 
compared for different ART regimes. Treatment with ART that has greater estimated 
distribution into the CNS has been associated with better cognitive performance in 
some studies, however results are not consistent.61 This strategy requires further 
evaluation in randomised clinical trials with larger sample sizes. 
 
There are currently no data on the use of ART to prevent, rather than treat, HAND. 
Cognitive impairment may develop soon after HIV transmission and whether a milder 
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degree of irreversible impairment can occur at higher CD4+ T-cell counts is not 
known.119 A study of US military personnel who were diagnosed and managed early 
during the course of HIV disease showed a low prevalence of cognitive impairment, 
comparable to matched HIV uninfected persons.65 The question of whether to start 
ART early to prevent cognitive impairment is being investigated in a sub-study of the 
Strategic Timing of AntiRetroviral Treatment (START) study, in an NIH-funded 
clinical trial in China (http://clinicaltrials.gov/ct2/show/NCT01340950), and in other 
projects.  
 
Although evidence is increasing that at least some modern antiretroviral drugs can 
cause neurotoxicity, whether this can lead to persistent cognitive impairment has not 
been systematically studied. The relationship between effective and toxic drug 
concentrations, the mechanisms of neurotoxicity, and approaches to identify patients 
who are suffering neurotoxicity in the clinic requires further investigation. Given the 
large degree of inter-individual variability in antiretroviral concentrations in CSF, and 
considerable variation in effectiveness vs. toxicity in the CNS observed between 
individuals, host genetic factors relating to ART distribution and metabolism in the 
CNS require further study. 
 
1.7.2 CSF/plasma discordance 
The clinical significance of CSF/plasma discordance is not known. To determine the 
extent to which this accounts for neurocognitive disease risk longitudinal studies are 
required to follow those with CSF/plasma discordance to determine the impact on 
cognitive function and the consequences for the development of ART resistance in the 
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CNS. Studies are needed to assess CSF and serum proteins and neuroimaging markers 
of inflammation to determine whether CSF/plasma discordance is associated with 
evidence of inflammatory up-regulation and neuroglial injury. 
 
In addition to associations of CSF/plasma discordance with HAND, studies are 
needed to determine whether on-going HIV replication in the CNS is associated with 
ART treatment failure systemically. At present the best approach to identify which 
patients would benefit from a lumbar puncture for measurement of HIV RNA in CSF 
is unclear. More work is needed to determine the clinical applications of CSF HIV 
resistance testing and the implications of drug resistant mutations in the CSF for 
systemic HIV control. 
 
The definition of CSF/plasma discordance should be standardised across studies and 
in clinical practice. Studies should determine the lowest level of CSF/plasma 
discordance associated with CNS inflammation and/or the detection of resistant virus 
in CSF. As increasingly sensitive HIV RNA assays become available for clinical use, 
the significance of discordance at lower levels also requires further study.  
 
1.7.3 HAND incidence and prevalence  
Whether patients who initiate suppressive ART early in disease are at risk of 
developing HAND is unclear from existing data. Studies of avireamic patients have 
produced HAND prevalence estimates ranging from 19-64%.27, 64 These discrepant 
findings may reflect differences in comorbidities and the severity of immune 
suppression prior to initiating ART. More work is needed to identify the most 
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influential risk factors in ideal patients who meet current clinical goals, i.e., they 
began ART at higher CD4+ T-cell counts, have durable aviraemia and few 
neuropsychiatric comorbidities.  
 
Future studies describing the incidence or prevalence of HAND should include at 
least two key elements: identification of the impact of co-morbid factors on 
neurocognitive functioning and close matching of normative control populations to 
the diversity of the target HIV population. Ideally, a core set of methods should be 
standardised to allow for comparison between studies. More research should be 
performed comparing the Frascati criteria with the more conservative approach that 
requires two impaired tests per cognitive domain to reduce the risk of 
misclassification.109 Authors of studies of HAND should be encouraged to publish the 
demographic characteristics of the normative control population used.  
 
The current approach to identifying cognitive impairment is focused on developing a 
research classification, not on clinical diagnosis. The 2007 Frascati criteria should be 
updated to provide practical guidance for clinicians; for example how to interpret 
cognitive functioning in the context of demographics and co-morbid factors. Further 
work is needed in this area to develop clinically useful methods of distinguishing 
HAND due to HIV disease (and therefore potentially amenable to earlier ART 
initiation, more potent ART, or ART directed at the CNS) from cognitive impairment 
related to other factors.  
 
	   59	  
1.7.4 Screening for HAND 
Screening for asymptomatic impairment requires further evaluation. At present, few 
systematic studies have evaluated the progression of ANI to MND; well-powered 
longitudinal studies are required to define the natural history of HAND. Despite a 
substantial body of evidence evaluating several HAND screening tools, no single, 
affordable, easy-to-perform screening test has proven adequately sensitive and 
specific across all clinical settings.20 The most appropriate techniques to screen for 
HAND remain to be determined. Computerised cognitive assessments require further 
evaluation in people living with HIV as these could potentially be administered 
quickly and inexpensively in clinic. 
 
While comprehensive neuropsychological assessment is appropriate for some 
patients, it is unlikely to be cost-effective for widespread adoption as a screening tool. 
Restricting such testing to those reporting cognitive symptoms on a screening 
questionnaire is an approach suggested by EACS,22 however self-report of symptoms 
can be unreliable in patients with cognitive difficulties.120 The approach of targeting 
symptomatic patients for further screening also warrants prospective investigation. 
 
Other tests have been evaluated for their diagnostic and prognostic potential for 
HAND. For example, soluble and cellular biomarkers in CSF or blood may be 
abnormal in patients with HIV suppression, however the implications for the 
development of cognitive impairment are not well understood.26 Many of these 
biomarkers correlate with cognitive performance at testing and also at follow-up,81 but 
none have yet been developed for clinical use. Advanced neuroimaging techniques 
such as magnetic resonance spectroscopy, amyloid positron emission topography 
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scanning, and functional magnetic resonance imaging may also be useful in some 
cases, and are the subject of further study.121, 122 Biomarkers and neuroimaging 
techniques require evaluation as screening tools, as well as to monitor response to 
ART and as endpoints in clinical trials. As the HIV-seropositive population ages, such 
techniques should be evaluated in older patients to distinguish HAND from other 
causes of cognitive impairment, such as Alzheimer’s disease.  
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2 Hypotheses 
CSF/plasma discordance is a common determinant of viral detection in plasma 
(addressed in chapter 5).  
Low CSF antiretroviral drug concentrations are an important determinant of ART 
failure in the CNS and lead to CSF/plasma discordance and resistance (addressed in 
chapters 4 and 5).  
Biomarkers of neuroinflammation are associated with CSF/plasma discordance and 
neurocognitive impairment (addressed in chapters 6 and 7).  
Pharmacogenetic factors such as CYP2B6 and ABCB1 genotype impact the 
distribution of antiretroviral drugs into the CSF (addressed in chapters 8 and 9).  
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3 General methods 
3.1 The PARTITION Study (chapters 4, 5, 6, 8 and 9) 
The Penetration of AntiRetroviral Therapy InTO the Nervous system (PARTITION) 
study was a multicentre UK study.  
 
3.1.1 Setting  
Patients were recruited from 13 centres in the United Kingdom: Royal Liverpool and 
Broadgreen University Hospitals NHS Trust, Brighton and Sussex University 
Hospitals NHS Trust, North Middlesex University Hospitals NHS Trust, Chelsea and 
Westminster Hospitals NHS Trust, NHS Lothian, Newcastle Upon Tyne Hospitals 
NHS Foundation Trust, Leeds Teaching Hospitals NHS Trust and Kings College 
Hospital NHS Foundation Trust. Sites recruiting to PARTITION A only were 
Imperial College Healthcare NHS Trust, Walton Centre NHS Foundation Trust, 
Central and North West London NHS Foundation Trust - Camden Provider Services 
(Mortimer Market Centre/University College Hospital), Heart of England NHS 
Foundation Trust and Pennine Acute Hospitals NHS Trust. 
 
3.1.2 Recruitment 
Subjects were prospectively recruited from two groups. 
 
3.1.2.1 PARTITION group A 
In PARTITION group A CSF and plasma samples were collected at the time of a 
clinically indicated lumbar puncture.  
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Inclusion Criteria 
• HIV positive adults (≥16 years) undergoing a lumbar puncture for any clinical 
indication. 
Exclusion Criteria 
• Children under 16 years. 
• Emergency lumbar puncture where there is insufficient time to discuss the 
study and obtain informed consent. 
 
3.1.2.2 PARTITION group B 
In PARTITION group B lumbar puncture was performed for research purposes.    
Inclusion Criteria 
• HIV positive adults (≥16 years), with at least 1 episode of unexplained HIV-1 
RNA detection ≥50 copies/ml within 12 months. 
Exclusion Criteria 
• Children and adolescents younger than 16 years. 
• Patients with a contraindication to lumbar puncture such as space occupying 
lesion, coagulopathy, low platelet count (<50x109/L), recent history of seizure, 
focal neurological signs, papilloedema on fundoscopy or infected skin over the 
needle entry site. 
• Patients for whom there is a clear alternative explanation for treatment failure, 
such as non-adherence (self reported adherence <95% on Modified 
Medication Adherence Self Report Inventory (MASRI) scale). 
• Patients lacking the capacity to consent for lumbar puncture. 
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3.1.3 Definitions  
CSF/plasma discordance 
CSF/plasma discordance was defined as CSF HIV-1 RNA levels >0.5 log10 higher 
than those measured in the simultaneous plasma sample, or >0.5 log10 higher than the 
lower limit of quantification of the standard HIV-1 assay (40 copies/ml) in those with 
unquantifiable HIV-1 RNA on standard testing or <40 copies/ml on sensitive testing.  
Discordance on sensitive testing 
CSF HIV RNA not >0.5log10 the lower limit of quantification of the standard HIV-1 
assay (40 copies/ml), ie. not meeting criteria for discordance given above. However 
when plasma HIV RNA is quantified by sensitive testing, discordance >0.5log10 is 
demonstrated. An example would be a subject with 20 copies/ml in plasma, and 100 
copies/ml in CSF. 
High discordance (chapter 6) 
CSF HIV-1 RNA >1log10 plasma.  
Low discordance (chapter 6) 
CSF HIV-1 RNA 0.5-1log10 plasma or discordance only detected on sensitive testing. 
This group represents subjects that would not be considered significant by some 
definitions of discordance. 
CSF viral escape  
Plasma HIV-1 RNA less than LLQ for the standard assay (ie 40 copies/ml), and CSF 
greater than 40 copies/ml.  
Residual HIV-1 RNA detection 
HIV RNA detection between 1 and 49 copies/ml.  
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Although the lower limit of quantification of the standard assay used in PARTITION 
was 40 copies/ml, the goal of ART is persistent suppression of HIV RNA, commonly 
interpreted as a viral load <50 copies/ml.41 
Ongoing HIV viraemia despite treatment 
At least 1 episode of unexplained HIV-1 RNA detection ≥50 copies/ml within 12 
months 
CNS infection excluded, suspected or confirmed 
On the basis of clinical findings and results of lumbar puncture the treating clinician 
was asked to determine whether CNS infection had been excluded. Those without 
“CNS infection excluded” were categorised as “CNS infection suspected” (abnormal 
CSF parameters without definite diagnosis) or “CNS infection confirmed” (a CNS 
pathogen identified).  	  
3.1.4 Data collection 
Written informed consent was taken from all patients enrolled. A separate section 
included a request for additional specific consent to store DNA for future studies, in 
line with published guidelines.123 Demographic and clinical information was obtained 
from the patient records by a study investigator or research nurse. Basic information 
(that could not be completed in retrospect, such as time since last dose of 
antiretroviral medication) was collected on a paper based CRF by the clinician at the 
time of lumbar puncture. Subsequently this information was added to other data, such 
as CD4, HIV viral load and lumbar puncture results, onto a secure online pseudo-
anonymised, password-protected CRF using OpenClinicaTM software. Each subject 
was assigned a unique identification code which was anonymously linked to 
information in the following areas: 
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• Demographic information 
o Age, gender, ethnic group. 
• Medical information 
o Date of HIV diagnosis. 
o Mode of infection 
o History of CNS infection. 
o Indication for lumbar puncture 
• Medication information 
o Current antiretroviral regimen, dose and time last taken. 
• Immunological markers 
o CD4 (current and nadir), HIV viral load. 
• The results of clinically indicated CSF tests (cell count, protein, glucose, 
culture)  
Consent was obtained such that if future studies required information on disease 
progression, participants could be contacted or their notes consulted. 
 
3.1.5 Sample collection 
Group A 
• CSF – A separate CSF sample of up to 3-5ml was taken. Surplus CSF left 
over after clinically indicated tests had been performed was collected. 
• Plasma – Approximately 10ml of whole blood centrifuged and plasma frozen 
in EDTA 
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Group B 
• CSF – Up to 8-12ml collected 
• Plasma – Approximately 15ml of whole blood centrifuged and plasma frozen 
in EDTA. 
All subjects 
• Whole blood – Approximately 5ml of whole blood frozen in EDTA 
Sample used for genetic analysis. 
• Serum – Approximately 5ml of whole blood centrifuged and serum frozen  
To measure biomarkers and albumin for CSF:serum albumin ratios. 
• PAXgene – Approximately 2.5ml of whole blood frozen in PAXgene RNA 
preservative.  
Vacutainers containing PAXgene were provided for isolation and purification 
of intracellular RNA.  
Samples were frozen at site at ≤ -20 ̊C before being transferred to a biobank at the 
department of Pharmacology and Therapeutics at the University of Liverpool where 
they were held at -80 ̊C. I undertook site visits and applied data checks.  
 
3.1.6 Adherence 
Medication adherence was assessed using the Modified Medication Adherence Self 
Report Inventory (MASRI) questionnaire. This is an abbreviated version of the full 
MASRI questionnaire which has been validated against HIV viral load.124  
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3.1.7 Cognitive and functional assessment  
Subjects in Group B underwent assessment with the following tools. Testing was not 
done in Group A as results could be confounded by intercurrent illness.  
 
Cognitive symptoms were assessed by asking subjects to answer whether they had 
problems with memory, reasoning and attention, as described by Simioni et al.27 
Subjects were considered to have an abnormal result when answering “yes, 
definitely” on at least 1 of the 3 questions.  
 
Subjects were screened for cognitive impairment using the International HIV 
Dementia scale. This scale uses 3 brief tests to assess motor speed, psychomotor 
speed and memory-recall. A score of less than 10 was considered abnormal.125  
 
Functional impairment was measured using the Instrumental Activities of Daily 
Living Scale.20, 91 The maximum score of 8 means no impairment in the following 
activities; telephoning, shopping, preparing food, housekeeping, laundry, travel, 
medications and finances. A score of 7 or less indicates impairment.  
 
Mood disorders were assessed using the Hospital Anxiety and Depression scale, 
addressing depressive (HAD-D) and anxious (HAD-A) symptoms separately. Patients 
were considered depressed or anxious if the HAD-D or HAD-A subscale score was at 
least 10 out of 21.126, 127  
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3.1.8 Safety 
Lumbar puncture is a safe and well tolerated procedure that does not cause excessive 
discomfort to the patient when performed effectively.128 Full informed consent was 
taken and a detailed patient information leaflet was provided explaining the potential 
risks of the procedure. The clinical team excluded contraindications to lumbar 
puncture such as raised intracranial pressure, coagulopathy or focal neurological 
signs. All patients received full blood count, coagulation screen and ophthalmoscopy 
prior to procedure. Brain imaging (CT/MRI) was not required prior to LP in the 
absence of reduced conscious level or focal neurological signs.129 The lumbar 
puncture was performed by an experienced clinician taking the usual precautions of 
site location, local anaesthesia and aseptic technique. 
 
Headache is the most common complication following lumbar puncture. This is 
usually mild and self-limiting.130 The use of the Sprotte atraumatic needle 
significantly reduces headache risk131 and these needles were provided for use in 
recruiting centres.  
 
3.1.9 Ethics 
Informed consent was obtained from all participants. The study was approved by the 
North Wales Research Ethics Committee (Central and East). The study was co-
sponsored by the University of Liverpool and the Royal Liverpool and Broadgreen 
University Hospitals NHS Trust.  
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3.2 Other cohorts (chapters 7 and 8)  
Other clinical cohorts include subjects from the CNS HIV AntiRetroviral Therapy 
Effects Research (CHARTER) study in the USA12 and patients with HIV and 
tuberculous meningitis from a study of early vs. late antiretroviral therapy in 
Vietnam.132, 133 These cohorts are described in more detail in chapters 7 and 8 
respectively.  
 
3.3 Laboratory testing 
3.3.1 Quantification of antiretroviral concentration in CSF and plasma; assay 
development (chapters 4, 5, 8 and 9) 
Antiretroviral concentrations were determined in CSF and plasma by tandem liquid 
chromatography-mass spectrometry (LC-MS). The analysis of compounds by LC-MS 
involves first producing gas phase charged molecular ions in the H-ESI source by 
application of a heat assisted electrical potential. The precursor (parent) ions are then 
selected according to their mass-to-charge ratio (m/z) in the first mass analyser 
(quadrupole 1) and pass into a collision cell (quadrupole 2) where they are bombarded 
with gas molecules (nitrogen) resulting in the formation of positively charged 
fragment (daughter) ions. Finally, the fragment ions are focused into a second mass 
analyser (quadrupole 3) and the intensity of each fragment ion is measured resulting 
in a chromatogram. The intensity of the fragment ions produced is proportional to the 
concentration of the analyte. Concentrations can be determined by comparison to the 
relevant calibrator of known concentration. An internal standard solution is included 
in the sample extraction 
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Drugs were extracted by protein precipitation (plasma) or directly injected 
(CSF).  Standard curves were made up in artificial CSF (Harvard Apparatus, 
Holliston, MA, USA), and matrix effects assessed by post column injection. Assays 
were validated against repeated runs of quality controls (inter and intra-assay 
variability) and EQA standards. All runs were performed in duplicate. 
 
3.3.1.1 Plasma assays 
Concentrations of 11 antiretrovirals in plasma (protease inhibitors: atazanavir, 
amprenavir, darunavir, lopinavir, ritonavir and saquinavir; non-nucleoside reverse 
transcriptase inhibitors: etravirine, nevirapine and rilpivirine; CCR5 receptor 
antagonist maraviroc; integrase inhibitor raltegravir) were simultaneously quantified 
in a combined assay as described elsewhere.134 The analytical ranges of this assay are 
given in Table 5.  
 
The nucleoside reverse transcriptase inhibitors lamivudine, tenofovir and 
emtricitabine were measured in plasma separately by two assays with different 
sensitivities. The analytical ranges are given in Table 6.  
 
3.3.1.2 CSF assay 
Concentrations of 10 antiretrovirals in CSF (protease inhibitors: lopinavir, ritonavir, 
amprenavir, atazanavir, darunavir; non-nucleoside reverse transcriptase inhibitors: 
rilpivirine, etravirine, nevirapine; integrase inhibitor raltegravir; CCR5 entry inhibitor 
maraviroc) were simultaneously quantified in a combined assay.  The analytical 
ranges of this assay are given in Table 7.  
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Table 5. Analytical ranges for combined plasma 11 ART assay.  
	  	  
 
Table 6. Analytical ranges for low/high concentration NRTI assay. 
	  	  
 
Table 7. Analytical ranges for combined CSF 10 ART assay. 
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3.3.1.3 Assay for the quantification of efavirenz and major metabolites (free and 
glucuronidated) in plasma and CSF (chapter 8) 
These methods relate to results presented in chapter 8. Efavirenz was charecterised in 
2 cohorts (PARTITION and a Vietnamese TB co-infected population), with 
quantification of the major metabolites and determination of the effect of 
glucuronidation. Freshly prepared standards and quality control samples (prepared in 
artificial CSF) and clinical samples (100uL) were transferred into labeled 7uL 
stoppered glass tube to which 100mL of acetonitrile was added. The samples were the 
evaporated to dryness at room temperature in a stream of nitrogen. The samples were 
then incubated at 37oC for 2h with 400mL of a solution containing 200 units of b-
glucuronidase from H. pomatia in 0.2M sodium acetate buffer (pH = 5). The samples 
were subsequently alkalinised with 20mL of potassium carbonate buffer (0.1M, pH = 
9.4) and extracted with 3 mL of a mixture of organic solvents ethylacetate:hexane 
(60:40 v/v). After centrifugation, the organic phase was evaporated to dryness, the 
residue reconstituted in 100uL of a mobile phase (50/50 v/v ACN/H2O in 1mM 
ammonium Acetate) and 20uL of this solution was analysed directly by LC-MS/MS 
on a Thermo Access Triple Quadrupole mass spectrometer.  Hexobarbital was used as 
internal standard. Gradient elution was on a reverse-phase C18 column using 1mM 
ammonium acetate in water and acetonitrile. Quantification was by selective reaction 
monitoring in negative ionisation mode. A 1 mg/mL solution of efavirenz, 8-hydroxy-
efavirenz, 7-hydroxy-efavirenz and internal standard solution was separately infused 
directly into the mass spectrometer at a flow rate of 8 µL/min in MS–MS scan mode 
using a syringe. This generated product ions of specific masses that can be used to 
characterise each compound. The fragmentation patterns and precursor ions ([M-H]-) 
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were monitored in the negative ion mode and these characteristic fragments were used 
for quantification of efavirenz, its metabolites and internal standard (Table 8). 
 
 
 
 
 
 
Table 8. Mass spectrometry assay for the quantification of efavirenz and major 
metabolites in plasma and CSF.  
EFZ, efavirenz; 8-OH EFZ, 8-hydroxy-efavirenz; 7-OH EFZ, 7-hydroxy-efavirenz; 
QC, quality control; SD, standard deviation; CV, coefficient of variability; LQC, low 
quality control; MQC, medium quality control; HQC, high quality control.  	    
Analytes QC 
Nominal 
Concentration 
(ng/mL) 
Mean Measured 
Concentration 
(ng/mL) 
Accuracy 
 
 %Bias (SD) 
Precision 
(%CV) 
 
Intra assay	  
EFV LQC 7.30 6.96 -4.60 (0.52) 7.51 
MQC 17.40 17.70 1.70 (1.55) 8.74 
HQC 34.90 36.16 3.61 (6.39) 6.39 
8-OH 
EFV 
LQC 8.10 7.87 -2.87 (0.60) 7.63 
MQC 16.30 15.19 -6.80 (1.17) 7.69 
HQC 35.00 32.81 -6.27 (2.04) 6.23 
7-OH 
EFV 
LQC 4.50 4.63 2.84 (0.38) 8.19 
MQC 9.00 9.09 0.96 (0.25) 2.79 
HQC 19.00 19.68 3.60 (0.57) 2.91 
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3.3.2 CNS penetration effectiveness (CPE) score 
The revised CPE score (2010) was calculated by assigning a predefined point to each 
component of the ART regimen, as proposed by Letendre et al.,24, 135 whereby a 
higher score corresponds to increased effectiveness. The score reflects the physic-
chemical, pharmacokinetic, and pharmacodynamic properties of a drug combined 
with clinical and virological data. See Table 3 in chapter 1.  
 
3.3.3 Quantification of HIV-1 RNA in CSF and plasma 
HIV-1 RNA levels were measured by the Abbott RealTime HIV-1 assay 
(Maidenhead, UK). The assay quantifies the viral load over the range of 40–
10,000,000 copies/mL (1mL input) and reports qualitative RNA detection >40 
copies/mL. The manufacturer indicates detection of 30, 20, and 10 RNA copies/mL in 
96%, 88%, and 68% of cases, respectively. 
 
3.3.3.1 Sensitive HIV-1 RNA assay (chapter 5) 
A modified assay was used for sensitive HIV-1 RNA testing in a subset of subjects 
with unquantifiable HIV-1 RNA levels on standard testing. Briefly, following venous 
and lumbar puncture for collection of EDTA blood and CSF respectively, paired 
plasma and CSF were ultra-centrifuged at 40,000rpm for 15 minutes and the pellet 
was resuspended in 1ml Basematrix (Alere, Stockport, UK). HIV-1 RNA was 
measured using automated RNA extraction (Abbott m24sp) and quantification 
(Abbott m2000), as previously described.136  
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3.3.4 Resistance testing (chapter 4) 
Discordant samples underwent sequencing of reverse transcriptase (RT, amino acids 1 
to 335) and protease (amino acids 1 to 99) to detect drug resistance mutations, as 
described elsewhere.137 Mutations were evaluated according to the Stanford HIV 
Drug Resistance Database.138 
 
3.3.5 Genetic testing (chapters 8 and 9) 
Genomic DNA was purified from stored samples using standard phenol-chloroform 
extraction methods. Allelic discrimination by real-time PCR was performed for 
individual single nucleotide polymorphisms (SNPs). CYP2A6 copy number was 
determined by real-time PCR. 
 
3.3.5.1 Haplotype structure 
In order to map haplotype structure across the CYP2B6 locus in chapter 8, I undertook 
a combined approach of genotyping known functional SNPs with tagging SNPs 
identified through HapMap (hapmap.ncbi.nlm.nih.gov). SNPs with a minor allele 
frequency (MAF) of >0.05 were identified within dbSNP 
(http://www.ncbi.nlm.nih.gov/SNP) at intervals of approximately 1 kb across the 
CYP2B6 locus at chr19q13.2 and an additional 5 kb up- and downstream of the gene. 
Where no SNPs with validated mean allele frequencies were available, the nearest 
positional SNP was included. A total of 196 individuals were genotyped for 16 SNPs 
using the MALDI-TOF-based Sequenom iPLEX system (Sequenom Inc., San Diego, 
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CA, USA) according to the manufacturer’s protocol. The following SNPs were 
included: rs1041983, rs1045642, rs11882450, rs1523130, rs2032582, rs2099361, 
rs2307424, rs2472677, rs28399433, rs3745274, rs7250601, rs763645, rs776746, 
rs8192711, rs8192712. Multiplex assays were designed using the software available 
at https://mysequenom.com/default.aspx. SNPs with mean allele frequency <0.05, call 
rate <90% or Hardy Weinberg p-value <0.0001 were omitted. 
 
3.3.6 Testing performed at clinical sites 
In the PARTITION study CSF cell count, protein and glucose measurements, 
microbiological investigations, and CD4 cell counts were performed as indicated in 
the centres of care by routine methods. Ethical permission was granted for CSF 
testing (including CSF white cell count, CSF HIV-1 RNA quantification and other 
tests) to be performed at local sites in clinical laboratories only when felt to be 
clinically indicated by the treating clinician. As the significance of these tests in 
asymptomatic patients was unclear it was felt that knowledge of these results by the 
clinician could lead to changes to management that would not have occurred had they 
not been enrolled in a research study. As CSF white cell count can only be accurately 
performed on fresh samples this parameter was not available for all subjects in group 
B.  
 
3.3.7 Measurement of cytokine and chemokine levels (chapter 6) 
Thirty-seven mediators (cytokines, chemokines and associated co-mediators) were 
assessed using a commercial cytometric bead array assay system (Procarta ® 
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Immunoassay kit, Panomic Solutions, Affymetrix ® Milano, Itay) in accordance with 
the manufacturers’ instructions. The mediators assessed were chosen from reviewing 
previous literature: granulocyte-colony stimulating factor [G-CSF], granulocyte-
macrophage-colony stimulating factor [GM-CSF], myeloperoxidase [MPO], CCL2 
[monocyte chemotactant protein 1], CCL3 [C-­‐C	   motif	   ligand	   3,	   monocyte 
inflammatory protein 1a], CCL4, CCL5 [regulated on activation normal T cell 
expressed and secreted], CXCL10 [inducible protein 10], vascular cell adhesion 
molecule [VCAM], intracellular adhesion molecule [ICAM], vascular endothelial 
growth factor [VEGF]a, and matrix metalloproteinases [MMP] 1, 2, 3, 7, 8, 9, 12 and 
13, interferon [IFN] a, b, o, g, tumour necrosis factor [TNF]a and its soluble receptors 
[TNFR1 and TNFR2] and TNFa-related apoptosis inducing ligand [TRAIL], IL1a, 1b, 
2, 4, 6, 8, 10 and 17a, IL17f, and IL1-receptor antagonist [IL1RA]. Analytes were 
assessed for all patient groups on 1 plate for MMPs and 1 plate for all other 
mediators. Fluorescence intensity was determined using a Bio-Rad platform (BioPlex 
Manager 4.1, Bio-Rad Laboratories ©, Hertfordshire, UK). Standards and samples 
were analysed in duplicate and the mean value used in analysis. Standard curves were 
adjusted at the points of fluorescence intensity saturation, to generate a sigmoid 
standard curve with 6-8 fluorescence intensity points. To avoid undetectable levels of 
mediators or missing data biasing the analysis, only mediators that were detected in at 
least 80% of the cohort were included in the analyses.139, 140 
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3.4 Statistical analysis  
All analysis was undertaken using SPSS version 22. In all chapters continuous clinical 
and demographic variables were compared by Student’s t-test if normally distributed, 
or by Mann-Whitney U if non-parametrically distributed. Visual checks were applied 
to determine normality. Categorical data was analysed using Chi squared or Fisher’s 
exact test.  
In chapters 4 and 5, median HIV RNA levels and drug concentrations were compared 
with the Mann-Whitney U test. Variables demonstrated to be significant in univariate 
analysis went forward for multivariate logistic regression with a forced entry method. 
A p value of 0.05 was used to determine statistical significance.  
In chapter 6 mediator concentrations between groups were compared with the Mann-
Whitney U test. Within cases, individual CSF mediator concentrations were 
correlated with CSF HIV-1 RNA using Spearman’s r. Multivariate analysis of 
mediator concentrations in this chapter is described in detail below (section 3.4.1). 
Statistical techniques employed in chapter 7 are described within the chapter.  
In chapter 8 the geometric mean of log10 drug/metabolite concentrations were 
compared between studies and between genotypes by Student’s t test 1 way ANOVA 
respectively. Pearson r was used to determine the correlation between continuous 
variables. In chapter 9, effects of ABCB1 genotype on drug concentration were 
assessed using the Kruskal-Wallis test.   
 
3.4.1 Two-Way Unsupervised Sample Clustering (chapter 6) 
CSF mediators significantly (p<0.01) associated with CSF/plasma discordance in 
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univariate analysis were included in a 2-way unsupervised hierarchical clustering 
based on the patterns of relative mediator concentrations. This approach offered an 
opportunity to examine the synergistic interactions of mediators and allow patients to 
be classified by their overall host mediator response. Subjects and then mediators 
were hierarchically clustered using the program Cluster (version 3.0), using the 
uncentered correlation score as the similarity metric and the average branch linkage 
method. Results were viewed as heat-maps using Tree View software 
(http://rana.lbl.gov/EisenSoftware.htm).  
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4 The PARTITION study; factors associated with 
CSF/plasma discordance of HIV 
4.1 Aims 
The aims of this study were to determine the prevalence of CSF/plasma discordance 
in a clinical cohort, and determine the factors associated with this phenomenon.   
 
4.2 Methods 
Subjects were recruited from the PARTITION study in 2 groups (see section 3.1).  
 
4.3 Results 
A total of 153 ART treated subjects were recruited, 113 (74%) from group A and 40 
(26%) from group B (Figure 4). Overall CSF and plasma HIV-1 RNA levels were 
directly correlated (Spearman r=0.510; p<0.0001). Median HIV-1 RNA level was 20 
copies/ml in both CSF and plasma. HIV-1 RNA was below 50 copies/ml in 113 
(74%) plasma and 115 (75%) CSF measurements. CSF/plasma discordance was 
detected in 20 (13%); in these subjects median HIV-1 RNA levels were 501 copies/ml 
(IQR 210,2016) in CSF vs. 20 copies/ml (IQR 20,20) in plasma (Figure 5).  
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Figure 4. Subgroups from the PARTITION study 	  
  
PARTITION A 
Clinical lumbar puncture 
n=113 
PARTITION B 
Research lumbar puncture to investigate 
viral persistence in plasma (chapter 5) 
n=40 
Total PARTITION 
cohort (chapter 4) 
n=153 
Subgroup with sustained viral 
suppression <50 copies/ml in plasma 
for 12 months (used as comparator to 
group B in chapter 5) 
n=39 
Sensitive testing in those with HIV 
RNA <50 copies/ml (chapter 5) 
n=49  
(24 from PARTITION A and 25 from 
PARTITION B) 
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Figure 5. HIV-1 RNA in plasma and CSF 
a. HIV-1 RNA in plasma and CSF in groups A and B combined; n=153 
b. Paired HIV-1 RNA in plasma and CSF in the 20 subjects with CSF/plasma 
discordance.  
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4.3.1 Factors associated with CSF/plasma discordance 
Differences in measured variables among subjects with and without CSF/plasma 
discordance are shown in Table 9. Nadir CD4, MSM risk group and black ethnicity 
were included in a multivariate logistic regression model; although the model was 
significantly associated with CSF/plasma discordance (p=0.013), no single variable 
made a significant contribution to the model suggesting these variables explain the 
same variation in the outcome. There was significant correlation between predictor 
variables: only 5 (5%) subjects in the MSM risk group were black, vs. 87 (81%) white 
(p<0.0001). Nadir CD4 was higher in white-MSM, median 173 cells/mm3 (IQR 
48,292) vs. 110 cells/mm3 (IQR 35,242), p=0.029. Raltegravir use was more frequent 
in discordant subjects and CSF	  white	  cell	  count	  was	  higher	  in	  discordant	  subjects.	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Table 9. Factors associated with CSF/plasma discordance. 
*Tested in 24 (60%) of subjects in group B (see section 3.3.6). 
MSM, men who have sex with men; IVDU, intravenous drug user; IQR, interquartile 
range; ART, antiretroviral therapy; PI/r, ritonavir boosted protease inhibitor; 
NNRTI, non-nucleoside reverse transcriptase inhibitor; NRTI, nucleoside/tide reverse 
transcriptase inhibitor; CCR5 antag, CCR5 receptor antagonist; CPE, CNS 
penetration effectiveness score 2010; CSF WCC, cerebrospinal fluid white cell count. 
  
Yes (n=20) No (n=133) p value
46 (43,50) 46 (41,54) 0.913
15 (75) 117 (88) 0.156
MSM 8 (40) 90 (68) 0.024
Heterosexual 9 (45) 31 (23) 0.054
IDU 0 (0) 3 (2) 1.000
Vertical tx 1 (5) 2 (2) 0.345
Not disclosed 2 (10) 7 (5) 0.334
White 11 (55) 98 (74) 0.111
Black 8 (40) 21 (18) 0.027
Asian 1 (5) 5 (4) 0.575
Other/mixed 0 (0) 7 (5) 0.595
10 (6.5,15.5) 9 (5,16) 0.833
Nadir 32 (21,256) 159 (49,281) 0.030
Current 374 (190,613) 464 (310,707) 0.163
ART at sampling, n (%)
PI/r 15 (75) 77 (58) 0.220
NNRTI 5 (25) 51 (38) 0.323
NRTI 18 (90) 114 (86) 1.000
RAL 6 (30) 15 (11) 0.035
MVC 4 (20) 8 (6) 0.053
7 (7,9.5) 7 (6,8) 0.250
11 (0,21) 0 (0,3) 0.018
3 (15.0) 14 (10.5) 0.469
Years since HIV diagnosis, median (IQR)
CD4, median cells/mm3 (IQR)
CPE, median (IQR)
CSF WCC*, median cells/mm3 (IQR)
Confirmed/suspected CNS infection, n (%)
CSF/plasma discordance
Age, years (IQR)
Gender male, n (%)
Risk group, n (%)
Ethnicity, n (%)
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Within group A 13 (12%) subjects had CSF/plasma discordance. There were no 
differences in indication for lumbar puncture between those with and without 
CSF/plasma discordance (p=0.972). The most frequent indications for LP in group A 
were to investigate cognitive symptoms, (n=50, 44%), and headache (n=20, 18%). 
Other indications for lumbar puncture were as follows: abnormal neurological 
examination (n=7), follow up CNS infection (n=8), seizure (n=5), measure CSF HIV 
RNA (n=3), in PIVOT (Protease Inhibitor Versus Ongoing Triple-therapy) clinical 
trial (n=3), peripheral neuropathy (n=2), suspected neurosyphilis (n=7), suspected 
encephalitis (n=2), suspected multiple sclerosis (n=1), suspected CNS malignancy 
(n=1), acute confusion (n=1), HTLV-1 infection (n=1), sepsis unknown source (n=1) 
and staging for CNS lymphoma (n=1). Based on the LP results CNS infection was 
confirmed or suspected in 3 (15%) patients with CSF/plasma discordance, and 14 
(11%) without; this difference was not statistically significant (p=0.469). In group A, 
self reported adherence was <95% in 2 (15%) of those with, and 12 (12%) of those 
without CSF/plasma discordance (p=0.361). Adherence was not reported in 19 (17%) 
subjects. Self reported adherence ≥95% was an inclusion criteria for group B. 
 
4.3.2 Pharmacokinetics 
Differences in measured antiretroviral concentrations in CSF and plasma are shown in 
Table 10. In the total cohort (n=153) time of sampling post ART was not significantly 
different between those with and without CSF/plasma discordance, median 15 hours 
(IQR 5.5,20) vs. 13 hours (IQR 5,16.5) respectively (p=0.238). 
 
There were no significant differences observed between groups in measured 
concentrations of the remaining antiretroviral drugs in plasma, or with any drugs in 
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CSF either in univariate analysis (Table 10) or when combined with time post dose in 
a multivariate model. No significant differences between groups were observed when 
time post dose was incorporated with CSF/plasma drug levels in a multivariate model. 
 
Median plasma darunavir concentrations were significantly lower in discordant 
subjects (p=0.023). Median time post darunavir dose was significantly longer for 
discordant vs. non-discordant subjects; median 18 hours (IQR 10.5,24) vs. median 7 
hours (IQR 3,16) respectively, p=0.007. Plasma darunavir levels were negatively 
correlated with time post dose (Spearman r=-0.413, p=0.002) (Figure 6). 
 
A logistic regression analysis was performed including time post dose and plasma 
darunavir concentration. Overall the model was significantly associated with 
CSF/plasma discordance (p=0.003), however neither parameter made a unique 
statistically significant contribution to the model (time post dose p=0.063, plasma 
darunavir concentration p=0.160) suggesting these variables explain the same 
variation in the data, ie. plasma darunavir concentrations were lower in discordant 
subjects as they were sampled later post dose.  
 
There was a non-significant trend to lower plasma lamivudine concentrations in 
discordant subjects (p=0.059), however this trend was lost when combined with time 
post dose in a multivariate model (p=0.509) as time post dose tended to be longer in 
discordant subjects receiving lamivudine (median 15 hours [IQR 8,22]) vs. non-
discordant subjects receiving lamivudine (median 7 hours [IQR 5,15]), p=0.085.  
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Table 10. Plasma and CSF antiretroviral drug concentrations in those with and 
without CSF/plasma discordance. 
P values were calculated for drugs with 6 or more measurements in each group. * not 
significant when combined with time post dose in a multivariate model (p=0.160). ** 
trend towards significance lost when combined with time post dose in a multivariate 
model (p=0.509) 
NS, not significant; ATZ, atazanavir; DRV, darunavir; ETV, etravirine; LPV, 
lopinavir; MVC, maraviroc; NVP, nevirapine; RAL, raltegravir; RPV, rilpivarine; 
RTV, ritonavir; EFZ, efavirenz; TDF, tenofovir; FTC, emtricitabine; 3TC, 
lamivudine; IQR, interquartile range.  
n Median (IQR) n Median (IQR) p value
ATZ 2 1459 (305.1,2614) 17 1038 (366.5,1672) NS
DRV 11 2168 (1196,2732) 44 3535 (2147,5915) *0.023
ETV 1 362.7 3 362.5 (72.51,724.6) NS
LPV 0 3 8731 (8206, 8807) NS
MVC 3 169.2 (117.9,178.5) 5 232.4,88.06,523.4) NS
NVP 0 10 4351 (2416,5004) NS
RAL 2 680.1 (122.8,1237) 9 736.4 (155.4,1465) NS
RPV 0 4 79.07 (45.99,95.07) NS
RTV 0 15 192.7 (69.04,282.5) NS
EFZ 3 3231 (714.8,6103) 24 1709 (1049,2480) NS
TDF 8 72.07 (34.89,106.5) 54 98.06 (63.19,180.3) 0.116
FTC 7 122.8 (45.54,248.9) 58 260.8 (93.42,610.5) 0.367
3TC 5 240.5 (46.71,632.3) 19 714.8 (136.3,1596) **0.059
ATZ 2 23.87 (1.950,45.80) 18 11.17 (3.857,17.18) NS
DRV 10 26.79 (19.63,93.75) 44 42.37 (19.69,86.54) 0.754
LPV 0 3 9.871 (6.386,15.02) NS
MVC 3 47.58 (16.61,78.03) 6 7.079 (2.296,9.282) NS
NVP 0 12 1497 (1183,2041) NS
RAL 3 19.82 (18.04,170.6) 11 21.30 (15.27,44.95) NS
EFZ 2 38.87 (28.06,49.68) 24 13.45 (9.07,20.97) NS
CSF HIV-1 RNA >0.5log10 plasma
Yes (n=20) No (n=133)
Plasma
CSF
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Figure 6. Plasma and CSF darunavir concentration over time post dose 
Darunavir concentration was negatively correlated with time post dose in plasma 
(Spearman r=-0.413, p=0.002) but not CSF (Spearman r=-0.186, p=0.186).  
Solid line linear regression, dashed lines 95% confidence intervals.   
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4.3.3 CSF resistance 
CSF from discordant subjects underwent sequencing (Table 11). Four CSF samples 
did not amplify despite repeated attempts. Two subjects had insufficient volume of 
CSF remaining for resistance testing. Protease inhibitor (PI) major resistance 
mutations were detected in 2 of 9 (22%) CSF samples; both were taking PIs at 
sampling. Resistance to NNRTI was detected in 4 of 9 (44%) CSF samples; 1 subject 
was receiving NNRTIs at sampling and 2 had historic NNRTI use. Resistance to 
NRTIs, including the M184V/I mutation associated with high-level resistance to 
lamivudine and emtricitabine and increased susceptibility to tenofovir, was detected 
in 9 of 12 (75%) CSF samples. Seven subjects were receiving either lamivudine or 
emtricitabine at sampling.  One subject (subject 16) was receiving tenofovir at 
sampling and had received lamivudine until 7 years prior to sampling. One subject 
(subject 17) was not taking NRTIs at sampling but had received emtricitabine and 
tenofovir until 1 year prior to sampling. Resistance to integrase inhibitors was 
detected in all 4 CSF samples from subjects receiving this drug at sampling.  
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   HIV-­‐1	  RNA	  copies/ml	   	   CSF	  resistance	  associated	  mutations	  
Subject	   Group	   Plasma	   CSF	   ART	  at	  sampling	   PI	   NRTI	   NNRTI	   INT	  
1	   A	   40	   1038	   TDF/FTC/DRV/r	   None	  	   -­‐	   -­‐	   -­‐	  
2	   A	   52	   1231	   TDF/FTC/RAL/MVC	   -­‐	   -­‐	   -­‐	   -­‐	  
3	   A	   3443	   13088	   3TC/AZT/EFZ	   -­‐	   None	  	   V108I,	  E138A	   	  
4	   A	   10817	   63010	   TDF/FTC/RAL	   -­‐	   None	  	   None	  	   L74I	  
5	   A	   <40	   400	   ABC/3TC/DRV/r/RAL	   -­‐	   -­‐	   -­‐	   -­‐	  
6	   A	   <40	   422	   TDF/FTC/ATZ/r	   -­‐	   T69S,	  M184I	   -­‐	   -­‐	  
7	   A	   <40	   335	   TDF/FTC/DRV/r	   -­‐	   -­‐	   -­‐	   -­‐	  
8	   A	   <40	   162	   3TC/AZT/DRV/r/MVC/ETR	   -­‐	   -­‐	   -­‐	   -­‐	  
9	   A	   <40	   129	   DRV/r	   -­‐	   -­‐	   -­‐	   -­‐	  
10	   A	   <40	   579	   ATZ/r/TDF/FTC	   V82AV	   M184V,	  T215I	   -­‐	   -­‐	  
11	   A	   <40	   1981	   DRV/r/RAL/MVC/3TC	   None	  	   M184V	   	  V108I	   N155H	  
12	   A	   <40	   195	   EFZ/TDF/FTC	   -­‐	   -­‐	   -­‐	   -­‐	  
13	   A	   <40	   405	   LPV/r/AZT/RAL	   None	  	   None	  	   None	  	   N155H	  
14	   B	   <40	   138	   TDF/FTC/DRV/r	   -­‐	   M184I	   -­‐	   -­‐	  
15	   B	   <40	   254	   EFZ/TDF/FTC	   -­‐	   -­‐	   -­‐	   -­‐	  
16	   B	   48	   2028	   DRV/r/TDF/RAL	   None	  	   D67N,	  K70R,	  
L74V,	  M184V,	  
T215Y,	  K219E	  	  
L100IL,	  
K103KN	  
T66I,	  Y143C	  
17	   B	   78	   3234	   DRV/r/MVC/ETR	   None	  	   A62V,	  K65R,	  
M184V	  
None	  	   -­‐	  
18	   B	   88	   1569	   TDF/FTC/DRV/r	   None	  	   M184I	   None	  	   -­‐	  
19	   B	   <40	   162	   TDF/FTC/DRV/r	   V82A	   D67N,	  M184V,	  
T215Y,	  K219Q	  
V108I	   -­‐	  
20	   B	   258	   3518	   ABC/3TC/DRV/r	   None	  	   L74LV,	  M184V	   None	  	   -­‐	  	  
 
Table 11. Viral detection and CSF resistance in subjects with CSF/plasma 
discordance.  
RAMs in bold are to ARVs taken at the time of sampling. RAMs in italics have been 
previously detected in plasma. The symbol “-“ represents samples not tested or unable 
to amplify; 5 CSF samples did not amplify despite repeated attempts (subjects 2, 5, 7, 
9 and 12), 1 sample only amplified for PI RAMs (subject 1), and 2 subjects had 
insufficient volume of CSF remaining for resistance testing (subjects 8 and 15). 
Subject 2 showed CCR5 tropic virus in CSF. Subject 4 had plasma testing showing no 
NRTI or NNRTI RAMs.  	  
UA, unable to amplify; RM, resistance mutation; PI, protease inhibitor; NRTI, 
nucleoside/tide reverse transcriptase inhibitor; NNRTI, non-nucleoside reverse 
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transcriptase inhibitor; INT, integrase inhibitor; ATZ, atazanavir; DRV, darunavir; 
LPV, lopinavir; ETV, etravirine; MVC, maraviroc; NVP, nevirapine; RAL, 
raltegravir; RPV, rilpivarine; r, ritonavir; EFZ, efavirenz; TDF, tenofovir; FTC, 
emtricitabine; 3TC, lamivudine; AZT, zidovudine. 
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4.4 Discussion 
CSF/plasma discordance was present in 13% of the study population overall which is 
consistent with most other reports,8, 9 although the CNS HIV Anti-Retroviral Therapy 
Effects Research (CHARTER) cohort reported that less than 2% of 1555 HIV 
infected subjects had CSF/plasma discordance.12 Resistance mutations to multiple 
ART classes were demonstrated in CSF of discordant subjects. Of note, CSF ART 
resistance mutations were demonstrated in all 12 samples successfully tested, 
including NRTI RAMs in 8 of 10 on NRTIs at sampling and raltegravir RAMs in all 4 
subjects on raltegravir at sampling. PI RAMs were less frequent, occurring in 2 or 9 
samples tested. In discordant group B subjects, in whom viraemia was generally too 
low to perform resistance testing in plasma, CSF examination revealed RAMs to the 
current ARVs in 5 of 6 samples tested. Analysis of resistance in most plasma samples 
was not possible due to low viral load. Selected plasma samples are currently 
undergoing digital PCR as part of an ongoing study on compartmentalisation (see 
section 10.2). No follow up data was obtained to determine whether those subjects 
developed resistance in plasma, however Table 11 shows that in many cases there was 
a past history of resistance in plasma.  
 
An association between CSF/plasma discordance and nadir CD4 has been 
demonstrated in in other studies,68 and is confirmed here, suggesting the presence of 
HIV in the CNS relates to a longer duration of viral replication and a lower immune 
status. Cognitive impairment has also been associated with nadir CD4;12, 16 it is not 
clear whether this is due to a ‘legacy effect’ of CNS damage sustained in advanced 
disease, or whether it represents an ongoing CNS inflammatory process and/or 
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seeding of virus during advanced immunosuppression. These data would suggest the 
latter as discordant viral detection is detected in those with a history of low CD4 
many years after the nadir, following immune reconstitution and plasma viral control. 
Whereas the former can be prevented by earlier diagnosis and ART initiation, the 
latter is potentially amenable to treatment with CNS targeted therapy. CSF white cell 
count was higher in discordant subjects as previously described suggesting a 
neuroinflammatory process in these subjects.26 Further work to characterise CSF 
inflammatory biomarkers in those with CSF/plasma discordance at different levels is 
reported in chapter 6.  
 
There is no universally accepted definition for CSF/plasma discordance; some 
definitions exclude those with <1log10 difference between CSF and plasma HIV-1 
RNA, 68 and others exclude those with a CSF viral load <200 copies/ml.8 Five 
subjects (subjects 8, 9, 12, 14 and 19) would be excluded by these criteria. Subject 19 
has extensive multiclass resistance in CSF despite a CSF HIV-1 RNA of 162 
copies/ml. Two subjects with CSF HIV-1 RNA 100-200 copies/ml (subjects 14 and 
19) had resistance-associated mutations including M184V/I which is associated with 
impaired replicative capacity. The significance of CSF/plasma discordance at low 
levels is unknown.  
 
Drug sampling was random which limited the ability to demonstrate associations with 
discordance. Pharmacokinetic modeling to calculate Cmin would be an alternative 
approach but was not undertaken as the sparse data was not rich enough for most 
drugs. When time post dose was taken into account with multivariate modeling there 
were no significant differences in measured antiretroviral concentrations between 
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groups in either plasma or CSF. The reasons why CSF drug levels did not correlate 
with discordance are not known. One explanation is that these measured 
concentrations may not reflect levels within brain parenchyma,49, 50 or levels within 
perivascular macrophages, a critical target of HIV in the brain.4 Although these data 
do not support measuring antiretroviral concentration in CSF in clinical practice, 
whether CSF antiretroviral drug concentrations relate to clinical outcomes (eg. 
cognitive functioning) or to neurotoxic side effects, was not examined. For many 
antiretroviral drugs measured, there were too few subjects receiving this medication at 
sampling to determine whether a statistically significant association with CSF/plasma 
discordance was present. This was due to the unselected nature of the cohort and the 
wide variety of antiretroviral regimen commonly used in clinical practice. The revised 
version of the CPE score has been associated with better HIV-1 RNA suppression in 
CSF relative to regimens scoring lower values.141 In this study there was no 
association of CPE score with the occurrence of CSF/plasma discordance, however 
this study was not set up to look for such an association. Prescriber bias has been 
demonstrated; patients with CNS problems may be more likely to receive an ART 
regimen with a higher CPE score.114 Subjects in group B were significantly more 
likely to be receiving raltegravir due the increased prescription of this treatment in 
patients with incomplete HIV-1 RNA suppression in plasma. In this study there was 
very little variability in CPE scores; 44% had a CPE score of 7 and median CPE score 
was 7 in all groups. This would further limit the ability of this study to determine 
differences between ART regimens with different CPE scores. Increased use of 
raltegravir in discordant subjects was unexpected. This may represent a history of 
plasma viral detection in these patients as is the case in group B (see chapter 5). Of 
note raltegravir resistance was detected in all 4 samples tested. These data suggest 
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that integrase inhibitors may be suboptimal when used to treat viral persistence in 
CSF, unlike the use of this class to treat viral persistence in plasma.  
 
4.5 Conclusions 
CSF/plasma discordance with drug resistance in CSF is not uncommon in subjects 
undergoing lumbar puncture for a clinical indication or to investigate unexplained 
HIV viraemia. This phenomenon is associated with nadir, but not current, CD4 count 
and did not appear to relate to ART concentrations in plasma or CSF. Definitions for 
CSF/plasma discordance excluding those with 0.5-1log10 difference may increase the 
chance of type 2 error.  
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5 PARTITION group B; CSF HIV-1 RNA detection in 
subjects with incomplete viral suppression in plasma  	  
5.1 Introduction 	  
Whether ongoing replication of HIV in a CNS sanctuary site can lead to failure of 
sustained suppression in blood (commonly interpreted as a viral load <50 copies/ml41) 
is not known (see section 1.4.2). Sensitive assays can now detect HIV-1 RNA below 
the 50 copies/ml threshold in a proportion of stably treated patients, however the 
source and significance of residual plasma HIV-1 RNA detection at this level remains 
controversial.70 
 
5.2 Aims  
The aim of this study was to investigate HIV-1 RNA levels and ART concentrations 
in the CSF in those with a) intermittent or persistent low-level plasma HIV-1 RNA 
detection above 50 copies/ml despite ART, and b) residual HIV-1 RNA detection 
below 50 copies/ml. 
 
5.3 Methods 
Subjects were recruited from the PARTITION study in 2 groups (see section 3.1). 
Forty cases of ongoing intermittent or persistent HIV-1 RNA detection in the last 12 
months were prospectively recruited in group B. This study was designed to allow 
selection of subjects from group A with durable virological suppression (plasma HIV 
RNA <50 copies for ≥1 years, no evidence of CNS infection) to act as controls. A 
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total of 39 subjects from group A were selected. Forty-nine subjects (24 group A, 25 
group B) with HIV-1 RNA <50 copies/ml underwent sensitive HIV-1 RNA 
quantification. See Figure 4 outlining substudy groups.  
 
5.4 Results 
5.4.1 PARTITION group B; CSF HIV-1 RNA detection in subjects with 
incomplete viral suppression in plasma  	  
In group B, 33 (83%) subjects had intermittent low-level viraemia in the preceding 12 
months, while the remaining 7 (17%) had persistent low-level viraemia, median 144 
copies/ml (IQR 90,279). Median CSF HIV-1 RNA was 20 copies/ml in both groups. 
Seven (18%) subjects in group B had CSF/plasma discordance which was 
significantly more than the comparison group in which there were no discordant 
subjects (p=0.012) (Figure 7).  
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Figure 7. CSF HIV-1 RNA in subjects with and without sustained plasma HIV-1 
RNA suppression 
a. CSF HIV-1 RNA in 40 subjects with intermittent or persistent HIV-1 RNA ≥50 
copies/ml (group B) vs. 39 subjects with consistent HIV-1 RNA suppression <50 
copies/ml. Dashed line is 50 copies/ml.  
b. Paired plasma and CSF HIV-1 RNA in the 7 subjects with CSF/plasma 
discordance. 
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Covariates which were significantly associated with plasma HIV-1 RNA detection 
≥50 copies/ml in the preceding 12 months were compared between patients with 
detectable HIV-1 RNA (n=40) and controls (n=39).  Significant associations were 
observed in CSF/plasma discordance and years since HIV diagnosis ( 
Table 12). No significant differences were observed with age, gender, ethnicity, 
nadir/current CD4 count or CPE score. ART regimen was not associated with a 
history of plasma viraemia, apart from increased raltegravir use in patients with 
detectable viraemia.  
 
CSF/plasma discordance was unable to be fitted to a logistic regression model as there 
is no variability in one of the groups (ie. no subjects with CSF/plasma discordance in 
the aviraemic group). A logistic regression model containing the 2 remaining 
significant variables from univariate analysis was significantly associated with HIV-1 
RNA detection ≥50 copies/ml within 12 months (p=0.006). Both variables: years 
since HIV diagnosis and treatment with integrase inhibitor, remained significant in 
the model (p=0.042 and 0.022 respectively) showing they were independently 
associated with the outcome. The model as a whole explained between 12% (Cox and 
Snell R square) and 16% (Nagelkerke R squared) of the variance in discordance, and 
correctly classified 67% of cases. The strongest predictor of outcome was treatment 
with integrase inhibitor, reporting an odds ratio of 0.192, indicating that treatment 
with an integrase inhibitor was associated with an 81% increase in HIV-1 RNA 
detection within 12 months. This is likely to reflect the use of integrase inhibitors to 
intensify ART in patients with ongoing viraemia.  
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Table 12. Factors associated with plasma HIV-1 RNA detection ≥50 copies/ml 
within 12 months.  
*Group B. **Subset from group A, excluding those with CNS infection, with 
persistent HIV-1 RNA suppression below 50 copies/ml for 12 months.  
MSM, men who have sex with men; IVDU, intravenous drug user; IQR, interquartile 
range; ART, antiretroviral therapy; PI/r, ritonavir boosted protease inhibitor; 
NNRTI, non-nucleoside reverse transcriptase inhibitor; NRTI, nucleoside/tide reverse 
transcriptase inhibitor; CCR5 antag, CCR5 receptor antagonist; CPE, CNS 
penetration effectiveness score 2010.  
  
Yes (n=40)* No (n=39)** p value
7 (18) 0 (0.0) 0.012
46 (40,52) 48 (41,57) 0.337
35 (88) 35 (90) 1.000
MSM 28 (72) 27 (68)
Heterosexual 9 (23) 9 (23)
IDU 0 (0) 1 (3)
Vertical 1 (3) 0 (0)
Not disclosed 1 (3) 3 (8)
White 34 (85) 27 (68)
Black 5 (13) 8 (20)
Asian 1 (3) 1 (3)
Mixed/other 0 (0) 3 (8)
9.6 (4.7,17.4) 12.1 (9.1,20.3) 0.039
Nadir 132 (43,325) 196 (88,289) 0.314
Current 520 (395,729) 523 (354,770) 0.936
PI 29 (73) 22 (56) 0.162
NNRTI 12 (30) 17 (44) 0.248
NRTI 33 (83) 34 (87) 0.756
RAL 10 (25) 1 (3) 0.007
MVC 1 (3) 2 (5) 0.615
7 (6,7) 7.0 (6,8) 0.923
0.557
CPE, median (IQR)
Plasma HIV-1 RNA detection !50 
copies/ml in past 12 months
CSF/plasma discordance, n (%)
Age, median years (IQR)
Male gender, n (%)
Risk group, n (%)
Ethnicity, n (%)
0.214
Years since HIV diagnosis, median (IQR)
CD4, median cells/mm3 (IQR)
ART, n (%)
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5.4.2 Cognitive and functional testing in Group B 
One subject (3%) had an abnormal International HIV Dementia Scale (score 9.5/12) 
consistent with modern prevalence data on HIV-associated dementia12. This subject 
had CSF/plasma discordance. One subject had abnormal Instrumental Activities of 
Daily Living scale; this subject also had CSF/plasma discordance but was a different 
subject to that with abnormal International HIV-Dementia Scale. Ten subjects (25%) 
were considered anxious, and 2 subjects (6%) were considered depressed. Eight 
subjects (20%) recorded abnormal responses to cognitive symptoms questionnaire. 
There were no statistically significant differences between subjects with and without 
CSF/plasma discordance in any of these tests.  
 
5.4.3 Pharmacokinetics 
No significant differences were observed between the groups in measured 
antiretroviral concentrations in plasma or CSF (Table 13). Trends to lower plasma 
darunavir and higher CSF efavirenz in group B were lost when combined with time 
post dose in a multivariate model (p=0.174 and 0.624 respectively). 
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Table 13. Plasma and CSF antiretroviral drug concentrations in group B vs. a 
suppressed comparison group.  
P values were calculated for drugs with 6 or more measurements in each group. 
Differences remained non-significant when combined with time post dose in a 
multivariate model; *p=0.174, **p=0.624.  
NS, not significant; ATZ, atazanavir; DRV, darunavir; ETV, etravirine; LPV, 
lopinavir; MVC, maraviroc; NVP, nevirapine; RAL, raltegravir; RPV, rilpivarine; 
RTV, ritonavir; EFZ, efavirenz; TDF, tenofovir; FTC, emtricitabine; 3TC, 
lamivudine; IQR – interquartile range. 	    
n Median (IQR) n Median (IQR) p value
ATZ 3 393.3 (202.3,1678) 7 1038 (713.8,1665) NS
DRV 20 2050 (1450,5710) 11 3838 (3489,6291) *0.079
ETV 2 543.5 (362.5,7724.6) 1 72.51 NS
LPV 1 8206 2 8769 (8731,8807) NS
MVC 1 178.5 2 236.0 (42.19,429.7) NS
NVP 2 13319 (4916,21723) 3 4870 (4468,5268) NS
RAL 6 863.0 (162.7,1360) 0 NS
RPV 1 89.04 1 97.08 NS
RTV 0 6 257.1 (65.44,287.4) NS
EFZ 6 1709 (1377,3586) 10 1327 (923.4,3433) 0.426
TDF 18 92.21 (47.80,174.1) 17 99.09 (67.35,181.8) 0.726
FTC 19 276.7 (55.31,527.5) 18 201.8 (72.60,709.8) 0.980
3TC 2 66.77 (35.11,98.42) 9 714.8 (120.8,1678) NS
ATZ 4 5.09 (2.337,17.93) 7 12.32 (1.95,14.84) 0.930
DRV 22 38.58 (25.42,93.12) 9 53.26 (20.50,93.23) 0.893
LPV 1 9.871 2 10.70 (6.386,15.02) NS
MVC 1 16.61 2 8.491 (5.627,11.35) NS
NVP 2 3870 (1880,5860) 4 1429 (1183,1977) NS
RAL 9 19.82 (16.51,48.31) 0 21.30 (15.27,44.95) NS
EFZ 6 23.95 (16.11,30.13) 10 13.10 (9.986,21.60) **0.073
Plasma HIV-1 RNA !50copies/ml in past 12 months
Yes (n=40) No (n=39)
Plasma
CSF
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5.4.4 CSF resistance  
The CSF resistance profiles of discordant subjects in group B (subjects 14-20) are 
given in Table 11 in chapter 4. All discordant CSF samples sequenced showed 
resistance mutations in CSF; one subject had insufficient CSF sample for sequencing. 
Five of 6 subjects showed resistance to drugs in use at sampling. PI major resistance 
mutations were detected in 1 subject on darunavir at sampling (subject 19). Resistance 
to NNRTIs was detected in 2 subjects. Neither were receiving NNRTIs at sampling 
but both had historic NNRTI use; subject 16 received nevirapine between 1996 and 
1997 and subject 19 received efavirenz between 2000 and 2001. Resistance to NRTIs, 
including the M184V/I mutation associated with high-level resistance to lamivudine 
and emtricitabine and increased susceptibility to tenofovir, was detected in all 6 CSF 
samples. Three subjects were receiving emtricitabine (subjects 14, 18 and 19), 1 
subject was receiving lamivudine (subject 20), and 1 subject was receiving tenofovir 
(subject 16) at sampling. Subject 16 had received lamivudine until 7 years prior to 
sampling. One subject with NRTI resistance (subject 17) was not receiving NRTIs at 
sampling but had received emtricitabine and tenofovir until 1 year prior to sampling. 
Resistance to integrase inhibitors was detected in the 1 subject on raltegravir at 
sampling (subject 16).   
 
One subject (subject 16) receiving tenofovir, raltegravir and ritonavir-boosted 
darunavir 600/100 mg twice daily showed multiple mutations comprising thymidine 
analogue mutations (TAMs: D67N, K70R, T215Y, K219E), L74V and M184V for 
the NRTIs, L100I and K103N for the NNRTIs, and Y143C for the integrase 
inhibitors. The simultaneous plasma sample was 49 copies/ml. The same RT 
resistance profile observed in the discordant CSF sample had been detected 10 years 
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previously in plasma virus sequenced after virological failure of zidovudine, 
lamivudine plus abacavir followed by abacavir, lamivudine plus efavirenz. The 
patient then started PI/r-based ART and between 2002 and 2008 and experienced 5 
consecutive HIV-1 RNA measurements between 50 and 542 copies/ml; three of these 
viremic samples were sequenced and two, collected while the patient was receiving 
tenofovir, atazanavir, fosamprenavir, and ritonavir, showed the protease mutation 
V32I but no RT mutations. In 2008 the patient started tenofovir, raltegravir and 
ritonavir-boosted darunavir (600/100 mg twice daily) and between 2008 and 2011 
experienced two further episodes of viremia (50 and 117 copies/ml respectively); one 
of the two samples was sequenced with no mutations detected in RT, protease or 
integrase.  
 
5.4.5 Sensitive HIV-1 RNA testing in the PARTITION study 
Median volume of plasma tested was 4.5ml (IQR 3,6); median volume of CSF tested 
was 4ml (IQR 3,7). There was no correlation between volume of sample tested and 
virus detection (Spearman r=-0.119, p=0.242). Overall significantly more CSF 
samples had no HIV-1 RNA detected (n=39) than plasma (p<0.0001).  
 
Thirty-two (65%) subjects had plasma HIV-1 RNA detection between 1-49 copies/ml, 
median 13 copies/ml (IQR 6,24). Seventeen (35%) subjects had no HIV-1 RNA 
detected in plasma; in these subjects the median plasma volume tested was 5ml (IQR 
3.5,5.75) giving a median sensitivity of detection of 7 copies/ml (IQR 5,7).   
 
All subjects with no HIV-1 RNA detection in plasma on sensitive testing, also had no 
virus detection in CSF on sensitive testing. Median CSF volume tested for 
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undetectable samples was 4ml (IQR 3,7) giving a median sensitivity of detection of 7 
copies/ml (IQR 3,7). Sensitivity of detection was calculated by the group that 
developed and applied the assay, details will be presented elsewhere.142  Ten (31%) 
subjects with residual HIV-1 RNA detection in plasma had HIV-1 RNA detection in 
CSF, median 19 copies/ml (IQR 4,167) (Figure 8). Viral detection in CSF was 
significantly more frequent in this group than in those without plasma viral detection 
(p=0.009). Three (9%) of these subjects met study criteria for CSF/plasma 
discordance (Table 11; subjects 14, 15 and 16). One further subject (group B) had 
CSF/plasma discordance only detected on sensitive testing; 4 copies/ml in plasma and 
40 copies/ml in CSF. The discordance rate was not significantly different between 
groups (p=0.542).  
 
Covariates which were significantly associated with residual plasma HIV-1 RNA 
detection below 50 copies/ml were compared between patients with undetectable 
HIV-1 RNA (n=17) and with those with 1-49 copies/ml (n=32) (Table 14). Time 
since HIV diagnosis was significantly longer in those with no residual HIV-1 RNA 
detection in plasma, however when combined with nadir CD4 in a multivariate 
logistic regression model, neither variable remained significant (p=0.159, 0.219 
respectively). It was not possible to include CSF HIV-1 RNA detection in the model 
due to lack of variability in one of the groups (ie no CSF HIV-1 RNA detection in the 
group without residual plasma HIV-1 RNA detection). No significant differences 
were observed with age, gender, ethnicity, nadir/current CD4 count or CPE score.  
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Figure 8. Low level HIV-1 RNA detection in CSF and plasma by sensitive assay 
a. CSF and plasma HIV-1 RNA in 49 subjects undergoing HIV-1 RNA quantification 
with sensitive assay 
b. CSF HIV-1 RNA in 17 subjects with no residual plasma HIV-1 RNA detected vs. 32 
subjects with plasma HIV-1 RNA detection between 1 and 49 copies/ml. Dashed line 
is at 50 copies/ml.   
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Table 14. Factors associated with residual HIV-1 RNA detection.  
*Variables were taken forward into a multivariate model. Neither nadir CD4 or years 
since HIV diagnosis remained significant in this model. **HIV-1 RNA detection in 
CSF could not be included in multivariate regression model due to lack of variability 
in one of the groups.  
MSM, men who have sex with men; IVDU, intravenous drug user; IQR, interquartile 
range; ART, antiretroviral therapy; PI/r, ritonavir boosted protease inhibitor; 
NNRTI, non-nucleoside reverse transcriptase inhibitor; NRTI, nucleoside/tide reverse 
transcriptase inhibitor; CCR5 antag, CCR5 receptor antagonist; CPE, CNS 
penetration effectiveness score 2010.  
  
<LLQ US assay 
(n=17)
1-49 copies/ml 
(n=33)
p value
0 (0) 11 (33) **0.009
 - 23 (4,254)
53 (47,59) 48 (41,55) 0.107
14 (82) 31 (94) 0.322
0.281
MSM 10 (59) 23 (74)
Heterosexual 6 (35) 8 (26)
IVDU 1 (5.9) 0 (0.0)
0.779
White 14 (82) 26 (79)
Black 3 (18) 5 (15)
Asian 0 (0) 1 (3)
Mixed 0 (0) 1 (3)
17 (7.5,27.0) 8 (3.5,17.0) *0.041
Nadir 82 (32,230) 178 (55,338) *0.092
Current 334 (102,414) 540 (379,841) 0.197
ART, n (%)
PI/r 14 (82) 20 (61) 0.2
NNRTI 6 (35) 12 (36) 1.000
NRTI 14 (82) 29 (88) 0.677
INI 1 (6) 6 (18) 0.398
CCR5 antag 0 (0) 3 (9) 0.542
7.0 (3.5,7.5) 7.0 (3.0,8.0) 0.233
Ethnicity, n (%)
Years since HIV diagnosis, median (IQR)
CD4, median cells/mm3 (IQR)
CPE, median (IQR)
Plasma HIV-1 RNA
HIV-1 detection in CSF, n (%)
CSF HIV-1 RNA, median copies/ml (IQR)
Age, years (IQR)
Male gender, n (%)
Risk group, n (%)
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5.4.6 Pharmacokinetics 
There were no significant differences in measured antiretroviral concentrations in 
plasma or CSF between the two groups (Table 15). No significant differences 
between groups were observed when time post dose was incorporated in a 
multivariate model. 
	  
Table 15. Plasma and CSF antiretroviral drug concentrations in those with and 
without residual HIV-1 RNA detection in plasma on sensitive testing.  
P values were calculated for drugs with 6 or more measurements in each group. 
NS, not significant; ATZ, atazanavir; DRV, darunavir; ETV, etravirine; LPV, 
lopinavir; MVC, maraviroc; NVP, nevirapine; RAL, raltegravir; RPV, rilpivarine; 
RTV, ritonavir; EFZ, efavirenz; TDF, tenofovir; FTC, emtricitabine; 3TC, 
lamivudine; IQR – interquartile range.   
n Median (IQR) n Median (IQR) p value
ATZ 3 1312 (871.3,1665) 2 1611 (47.01,3174) NS
DRV 10 3920 (2329,10692) 14 4425 (1759,5726) 0.400
ETV 1 362.5 0 NS
MVC 0 1 617 NS
NVP 2 3838 (2408,5268) 4 4692 (4222,17521) NS
RAL 0 4 863.0 (289.6,1155) NS
RPV 1 97.08 1 89.04 NS
RTV 6 111.4 (42.48,272.7) 2 207.3 (169.8,244.9) NS
EFZ 2 2356 (1934,2778) 6 2359 (1723,3586) NS
TDF 9 156.2 (93.85,226.0) 12 97.20 (68.86,157.1) 0.128
FTC 8 605.7 (461.6 (922.5) 13 275.9 (144.8,751.0) 0.140
3TC 2 2003 (1783,2224) 5 610.2 (282.1,1605) NS
ATZ 3 14.69 (12.32,19.01) 3 3.50 (1.95,25.28) NS
DRV 10 40.46 (16.21,94.13) 14 39.11 (25.95,81.02) 0.910
MVC 0 2 5.567 (2.602,8.531) NS
NVP 2 958 (751.8,1165) 4 2199 (1612,5024) NS
RAL 1 24.69 6 18.43 (14.21,27.78) NS
EFZ 2 22.92 (20.29,25.56) 6 24.22 (18.62,30.13) NS
Plasma HIV-1 RNA
<LLQ US assay (n=17) 1-49 copies/ml (n=33)
Plasma
CSF
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5.5 Discussion 
Importantly, discordance was observed in 18% of patients with intermittent or 
continuous low-level viraemia (group B) compared with no discordance in HIV-
positive patients with durably and optimally suppressed plasma viral loads. This 
suggests that a significant proportion of HIV-positive patients with low-level viraemia 
despite ART have suboptimal control of virus replication within the CNS. The clinical 
significance of this finding remains unclear, but studies are currently investigating the 
link between ongoing replication during ART and immune activation, cardiovascular 
risk, and virological rebound. One interpretation of these findings could be that 
ongoing replication of HIV in a CNS sanctuary site and the development of ART 
resistance in this compartment is responsible for viral detection in plasma in a 
proportion of patients. In 7 subjects at least part of the resistance detected in CSF 
virus was consistent with the previous history of failure and older resistance tests in 
plasma. This combined with the observed impact of low nadir CD4, suggest that 
advanced immune suppression may allow the establishment of a viral reservoir in the 
CNS that is only partially responsive to ART. This virus may then continue to evolve 
and develop resistance to some ARVs, for example raltegravir, and thus become less 
susceptible to suppression than virus in peripheral blood. Low-level viraemia with a 
genetically different virus may originate from a similar process of incomplete 
suppression at other sites such as lymphoid tissue. Alternatively, intermittent 
reseeding of virus into the CNS during periods of systemic replication due to another 
cause (eg. non-declared poor adherence) may have established compartmentalised 
CNS infection. 
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All discordant CSF samples sequenced showed resistance mutations in CSF. This 
suggests that the CNS may be the source of plasma virus in patients with low-level 
treatment failure. Subject 16 appears to demonstrate seeding of virus into the CNS 
early in infection, which has persisted despite changes to antiretroviral therapy. This 
phenomenon is currently being examined further with digital PCR and phylogenetic 
analysis of virus in CSF and plasma in subject 16 and other discordant subjects at the 
Center for Disease Control and Prevention (CDC) as part of an MRC Early Career 
Award (see section 10.2.1).  
  
Of note, most subjects had HIV viral loads in plasma too low to perform resistance 
testing. Determining the presence of resistant virus, and hence the ability to make 
changes to antiretroviral treatment with the knowledge of resistance profile, would 
only be possible by performing lumbar puncture in otherwise asymptomatic 
individuals. These data suggest that performing lumbar puncture to quantify CSF 
HIV-1 RNA and determine viral resistance in this compartment may be a useful 
strategy in those with blips, or systemic treatment failure. 
 
The source and significance of residual plasma HIV-1 RNA detection <50 copies/ml 
remains unclear; this may be due to release of latent virus from resting memory T-
cells and therefore not capable of replication, or be due to ongoing HIV-1 replication 
in sanctuary sites such as the brain. Patients with a viral load <50 copies/ml 
monitored with the Abbott RealTime assay, plasma HIV-1 RNA levels between 40 
and 49 copies/ml and to a lesser extent qualitative RNA detection below 40 copies/ml 
have been associated with a markedly increased risk of viral load rebound above 50 
copies/ml and above 400 copies/ml over 12 months of follow-up.137 Recent analyses 
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have confirmed these initial findings.143, 144 These observations indicate that a subset 
of patients with plasma HIV-1 RNA detection below the 50 copies/ml threshold may 
be experiencing on-going virus replication. In this study residual HIV-1 RNA 
detection below 50 copies/ml on sensitive testing was significantly associated with 
CSF HIV-1 RNA detection, suggesting that in some cases the CNS may be the source 
of HIV-1 detection in the plasma. This has implications for targeting antiretroviral 
treatment to the CNS and the eradication of HIV from sanctuary sites. Determining 
low level viraemia in this setting may represent a clinical use for sensitive HIV-1 
RNA assays, currently only available as a research tool in most centres. Three 
subjects had CSF/plasma discordance, however this was not significantly different to 
the absence of CSF/plasma discordance in 17 without HIV-1 detection in plasma. In 1 
additional case discordance was detected only on sensitive testing (plasma 4 
copies/ml, CSF 40 copies/ml). The significance of discordance detected at this level 
remains controversial and is examined further in chapter 6.  
 
This study has several limitations. Prospectively recruiting persistently suppressed 
patients would have been methodologically preferable than selecting the control 
population from group A, but this was not felt to be ethically justified. However, as 
discordance is more frequent in clinically indicated lumbar punctures8, 9, 39, 71 than 
those performed for research purposes,9, 39 this would be more likely to lead to an 
increase in CSF/plasma discordance rates in the control group and an underestimation 
of the difference with group B; hence a type 1 error would be more likely than type 2.  
 
This study has shown association, rather than causality. Ongoing phylogenetic 
analysis will help to address this by determining the genetic origins of virus in CSF 
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(section 10.2.1). It is intended that the effect of treating CSF/plasma discordance on 
viral persistence in plasma will be addressed in a longitudinal follow-on study 
(section 10.2.2).  
 
Sensitive HIV-1 RNA testing remains a research tool. The variability in viral 
detection at very low levels over time within a single individual has not been 
determined. Whether CSF/plasma discordance is associated with viral detection in 
plasma <50 copies/ml was not shown in this study and requires clarification in larger 
cohorts.  
 
5.6 Conclusions 
The CNS may be the source of ongoing HIV-1 replication in a proportion of patients 
that fail to suppress below 50 copies/mL in plasma, as well as those with residual 
plasma HIV-1 RNA detection between 1-49 copies/mL. This has implications for the 
management of low-grade viraemia and ‘blips’, both in terms of stratifying patients 
for lumbar punctures and tailoring treatment for effective suppression in the CNS.	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6 CSF/plasma HIV-1 RNA discordance above 0.5log10 
associated with raised expression of CSF biomarkers 
compared with non-discordant subjects 
  
6.1 Introduction 
The clinical significance of CSF/plasma discordance remains to be determined (see 
section 1.4.1). There is currently no consensus on the degree of discordance between 
CSF and plasma HIV-1 RNA that should be considered clinically significant.8, 9, 68  In 
addition, sensitive testing can now detect HIV-1 RNA below the traditional threshold 
of 50 copies/ml. However the source and significance of CSF/plasma discordance at 
this low level remains controversial.20, 70 Pro-inflammatory mediators have been 
shown to be raised in the CSF of some HIV positive individuals and in some cases 
this has been linked to cognitive impairment, however no single mediator has a strong 
enough correlation with cognitive status to be a clinically useful biomarker alone and 
a combination of biomarkers may be more useful.81 
 
6.2 Aims 
This nested case-control study aimed to use a cytometric bead array system to 
determine whether a panel of CSF cytokines, chemokines and associated mediators 
differed in subjects with CSF/plasma discordance compared with non-discordant 
subjects. Furthermore this study aimed to examine the relationship between mediator 
profile and CSF/plasma discordance at different levels. 
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6.3 Methods 
6.3.1 Study population 
Subjects were recruited from the PARTITION study in 2 groups (see section 3.1). 
Subjects with confirmed or suspected CNS infection were excluded. 
 
6.3.2 Selection criteria  
Discordance was defined as HIV-1 RNA >0.5log10 a simultaneous plasma sample, or 
in those with unquantifiable plasma HIV-1 RNA >0.5log10 the lower limit of 
quantification (ie. 40 copies/ml). Subjects were categorised as “high discordance” if 
CSF HIV-1 RNA was >1log10 plasma. Subjects with 0.5-1log10 discordance, or with 
discordance only detected on sensitive assay, were categorised as “low discordance”. 
Low discordance represents a group that would be excluded by some definitions of 
discordance. CSF viral escape was defined as plasma HIV-1 RNA less than lower 
limit of quantification for the standard assay (ie 40 copies/ml), and CSF greater than 
40 copies/ml. 
 
For controls, we looked among all participants in the partition study who did not have 
discordance, and selected those with a plasma HIV RNA-1 which most closely 
matched that of subjects with discordance.  
 
6.4 Results 
Discordant subjects: Nineteen cases of CSF/plasma discordance were identified in 
18 subjects (1 subject had 2 discordant results in CSF collected at an interval of more 
than 2 years). Eleven (58%) had high discordance and 8 (42%) had low discordance; 
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of those with low discordance, 3 had CSF/plasma discordance only detectable on 
sensitive testing - plasma and CSF HIV-1 RNA 4, <7, <10 and 40, 74, 51 copies/ml 
respectively. Median HIV-1 RNA in plasma was 20 copies/ml (IQR 10,52) and in 
CSF was median 422 copies/ml (IQR 138,1981).   
 
Non-discordant subjects: Twenty-one non-discordant subjects were selected. 
Median HIV-1 RNA in plasma was 20 copies/ml (IQR 8,50) which was not 
significantly different to discordant subjects (p=0.655). Twelve (57%) subjects had 
low CSF HIV-1 RNA demonstrated on sensitive assay; median HIV-1 RNA in CSF 
was 4 copies/ml (IQR 4,20). HIV-1 RNA in CSF was lower than plasma in 15 (71%) 
subjects, the same as plasma in 5 (24%) subjects, and greater than plasma in 1 (5%) 
subject (plasma <40, CSF 69 copies/ml).  
 
6.4.1 Subject characteristics 
Demographic, clinical and laboratory parameters did not differ between discordant 
and non-discordant subjects, with the exception of CSF pleocytosis which was more 
frequent in those with discordance (Table 16). 
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Table 16. Subject characteristics in 19 cases of CSF/plasma discordance >0.5log10 
vs. 21 without discordance.  
IQR, interquartile range; MSM, men who have sex with men; IVDU, intravenous drug 
user; LP, lumbar puncture; CPE, CNS penetration effectiveness score (2010); ART, 
antiretroviral therapy; PI/r, ritonivir boosted protease inhibitor; NNRTI, non 
nucleoside reverse transcriptase inhibitor; RAL, raltegravir; MVC, maraviroc. 
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CSF white cell count was significantly higher in the discordant group (median 4.5 
cells/ul [IQR 0,18]) than in the non-discordant group (median 0 cells/ul [IQR 0,1]); 
p=0.003. CSF white cell count was recorded in 10 of 16 (63%) subjects in group B 
(not all group B subjects had CSF white cell count measured as this was not a 
condition of the study protocol (see section 3.3.6). Eight (53%) of 15 discordant 
subjects had normal CSF white cell count (ie. ≤4cells/ul); of these 6 (40%) had no 
measurable white cells in CSF (ie. <1cell/ul). All subjects in the non-discordant group 
had normal CSF white cell count; 14 (74%) had no measureable cells (Figure 9).  
 
 
 
 
Figure 9. CSF white cell count (WCC) in subjects with and without CFS/plasma 
discordance 
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6.4.2 CSF mediators 
The following mediators had measurements at or below the lower limit of 
quantification in ≥80% of measurements (ie. ≥30 samples) and hence were excluded 
from further analysis (see section 3.3.7): GCSF, GM CSF, IFNa2, IFNb, IL17a, IL17, 
IL2, IL4, TNFa, VEGFa, MMP1, 3, 8, 9, 12 and 13. 
 
6.4.2.1 Univariate analysis  
Nineteen (90%) of 21 CSF mediators were significantly higher in discordant than 
non-discordant subjects (Table 17); these broadly pro-inflammatory mediators 
included chemokines (CXCL10, CCL3, CCL4, CCL5), interferons (IFNy), 
interleukins (IL1a, IL1b, IL6, IL8, IL10) and their receptor antagonists (IL1RA), 
tumour necrosis factors (TNFb) with their receptors (TNFR1, TNFR2)	   and	   the	  related	   apoptosis	   inducing	   ligand	   (TRAIL), myeloperoxidase enzyme (MPO), 
adhesion molecules (ICAM, VCAM) and metalloproteinases (MMP2). There were no 
significant differences between CSF mediator concentrations in subjects with high vs. 
low discordance. CSF mediator concentrations significantly correlated with CSF 
HIV-1 RNA for 9 mediators; IL10, IL1a, CXCL10, CCL3, CCL4, CCL5, VCAM, 
TNFR2 AND TRAIL. The 4 CSF mediators with the most significant correlation with 
CSF HIV-1 RNA (CXCL10, CCL3, VCAM and TNFR2) are shown in Figure 10.  
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Table 17. CSF biomarker concentrations  
Nineteen of 21 CSF mediators were significantly higher in discordant than non-
discordant subject in univariate analysis. There were no significant differences 
between CSF mediator concentrations in subjects with high (CSF HIV-1 RNA >1log10 
plasma) vs. low (0.5-1log10 plasma or discordant only on sensitive testing) 
discordance. Nine CSF mediator concentrations correlated with CSF HIV-1 RNA.  
Values are median pg/ul (IQR). P values are by Mann-Whitney-U or Spearman r 
correlation. CSF, cerebrospinal fluid; RNA, ribonucleic acid.  
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Figure 10. CXCL10, CCL3, VCAM and TNFR2 concentrations in high/low 
discordance vs. non-discordant subjects, and correlation with HIV-1 RNA. 
CXCL10, CCL3, VCAM and TNFR2 concentration (a-d respectively) were 
significantly higher in discordant vs. non-discordant subjects. No significant 
differences were observed between subjects with high (CSF >1log 10 plasma) vs. low 
(CSF 0.5-1log10 plasma or discordant only on sensitive testing) degrees of 
discordance. Subjects discordant only on sensitive testing are represented with an 
open circle. Mediator concentrations correlated with CSF HIV-1 RNA (e-h).  
Non-disc, non-discordant; Low-disc, low-discordant; High-disc, high-discordant; ns, 
not significant; CXCL10, inducible protein 10; VCAM, vascular cell adhesion 
molecule; CCL3, C-C motif ligand 3 AKA monocyte inflammatory protein 1a; 
TNFR2, tumour necrosis factor receptor 2.  
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6.4.2.2 Cluster analysis of subjects 
The subjects grouped into 2 main clusters (Figure 11). These clusters corresponded to 
CSF/plasma discordance (p<.0001, Fisher’s exact test). In cluster 1 all mediators had 
relatively high abundance; this cluster included 18 discordant subjects and 3 non-
discordant subjects. Grouped in cluster 1 were all subjects with CSF HIV-1 RNA 
>1log10 plasma, all with CSF HIV-1 RNA 0.5-1log10 plasma, and 2 of the 3 with 
CSF/plasma discordance only on sensitive testing. In cluster 2 all mediators had 
relatively low abundance; this cluster included 18 non-discordant subjects and 1 
discordant subject; this subject was only discordant on sensitive testing (CSF HIV-1 
RNA 74, plasma <7 copies/ml). Two of the 3 subjects with CSF viral escape not 
meeting criteria for CSF/plasma discordance were in cluster 2.  
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Figure 11. Heat map displaying the relative concentration of  mediators in subjects 
with and without CSF/plasma discordance.  
Samples and mediators were organised via an unsupervised hiarachical clustering 
algorithm along the horizontal and vertical axes respectively. Twenty-one subjects 
without discordance are labeled on the x-axis with the symbol “o”. Nineteen subjects 
with discordance are indicated with the symbol “+++/++/+”; discordant subjects 
with CSF HIV-1 RNA >1log10 plasma are labeled “+++” (n=11), CSF 0.5-1log10 
plasma are labeled “++” (n=5) and those with discordance only present on sensitive 
HIV-1 RNA testing are labeled “+” (n=3). Tile colour indicates relative mediator 
concentration: red, increased; green, decreased; black, at median concentration (for 
the samples). On the horizontal axis the subjects segregated into 2 main clusters, 
cluster 1 and 2, corresponding significantly to discordant and non-discordant 
subjects respectively (p<0.0001). Grouped in cluster 1 were all subjects with CSF 
HIV-1 RNA >1log10 plasma, all with CSF HIV-1 RNA 0.5-1log10 plasma, and 2 of the 
3 with CSF/plasma discordance only on sensitive testing. One subject with 
discordance only on sensitive testing (CSF HIV-1 RNA 74, plasma <7 copies/ml) was 
grouped in cluster 2. 
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6.4.2.3 Cluster analysis of mediators 
CSF mediators significant in univariate analysis clustered into 2 main sets with 2 
mediators (IL1RA and CCL5) outlying these sets (Figure 11). The first set included 
IL6, IL1b, IL10, TRAIL and MPO; the second set included TGFb, CCL4, IL1a, 
CXCL10, VCAM, IFNy, IL8, CCL3, ICAM, TNFRII and TNFRI.  
 
6.5 Discussion 
These data demonstrate that CSF/plasma discordance is associated with the increased 
expression of CSF mediators. Clinical outcomes were not assessed in this study, 
however these mediators are broadly pro-inflammatory and risk leading to neuronal 
damage if chronically raised. Raised CSF concentrations of many of these have been 
shown to correlate with cognitive impairment in patients with HIV infection, although 
no single mediator has a strong enough correlation with cognitive status to be a 
clinically useful biomarker and a combination of biomarkers may be more useful.81. 
The associations of these mediators with CNS disease in HIV positive populations has 
been reviewed by Brew and Letendre and Morris et. al.26, 81  
 
Interleukins produced by macrophages such as IL-1, IL-6, IL-8 and IL-10 have been 
associated with cognitive impairment in HIV infected adults and children, although 
most studies were in the pre/early-HAART era. TNFa is produced by macrophages 
and microglia and is involved with immune regulation and inflammation. CSF levels 
have been associated with brain injury and TNFa mRNA levels are elevated in the 
brain tissue of cognitively impaired HIV infected patients. Although >80% of TNFa 
measurements were below the limit of quantification in this analysis, levels of the 
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closely related proteins TNFR1, 2 and TRAIL were associated with discordance. CSF 
levels of interferons such as IFNa (excluded from analysis as >80% below limit of 
quantification), and to a lesser extent IFNg, have been associated with cognitive 
impairment in HIV. Levels of the interferon-inducible protein CXCL10 (IP-10) in 
CSF has been correlated with CSF HIV RNA and higher levels have been associated 
with adverse neurological outcomes. Chemokines CCL3, 4 and 5 (MIP1b, MIP1a and 
RANTES) bind CCR5 and are involved in monocyte chemotaxis and HIV entry into 
microglia and lymphocytes. They have been identified in brain tissue of a simian SIV-
encephalitis model. The chemokine CCL2 (MCP-1) is associated with chemotaxis of 
monocytes across the blood-brain barrier and has been associated with cognitive 
impairment in several studies in HIV positive populations in the pre and post-HAART 
era; surprisingly in our study levels were not significantly associated with 
discordance. TGFb modulates the inflammatory responses of cytokines and 
macrophage activation and CSF levels are raised in HIV infected patients with 
cognitive impairment. Adhesion molecules ICAM and VCAM mediate adhesion of 
monocytes and lymphocytes to vascular endothelium and promote monocyte 
trafficking across the blood-brain barrier. CSF levels are associated with CNS 
inflammation, blood-brain barrier damage and are raised in HIV encephalopathy in 
the pre-HAART era.26, 145  
 
CSF pleocytosis was more frequent in the discordant group, however the observed 
clustering is not purely an epiphenomenon of CSF pleocytosis as the majority of 
subjects did not have pleocytosis above 4 cells/ul and almost half had no measurable 
white cells in CSF.  
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The majority of subjects with low CSF discordance had raised CSF mediator 
concentrations in a similar pattern to those with high discordance. Only 1 low 
discordant subject had low CSF mediator concentrations and was grouped with the 
non-discordant cluster (this subject was discordant only on sensitive testing). This 
suggests that the criteria for CSF/plasma discordance used in some studies (ie. 
excluding subjects with <1log10 difference and/or <200 copies/ml in CSF) may risk 
type 2 error.8, 68 These data suggest that the lower cut-off of 0.5log10 should be 
considered, both in clinical practice and future research studies. This is consistent 
with our previous work demonstrating resistant HIV-1 in CSF, including M184V 
which is associated with decreased replicative capacity, in subjects with 0.5-1log10 
discordance and <200 copies/ml in CSF (Table 11).142  
 
Subjects with higher degrees of CSF/plasma discordance trended to higher CSF 
mediator concentrations. This effect was not strong and the difference between low 
and high discordant groups was not statistically significant for any single mediator. 
This is consistent with data from the CNS HIV Antiretroviral Therapy Effects 
Research (CHARTER) study, the largest cohort in this area, which found that 
although the absolute level of CSF HIV RNA was not related to cognitive 
performance, the presence of discordant virus was.39  
 
Reports have suggested that CSF HIV-1 RNA detection at levels below 50 copies/ml 
may be associated with cognitive impairment.39, 69 In this study, 2 of the 3 subjects 
with CSF/plasma discordance only detected on sensitive testing had raised CSF 
mediator profiles grouped with other discordant subjects. Although the numbers here 
are small, these data support the MIND exchange consensus report recommendations 
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that sensitive HIV-1 RNA testing should be considered in those with neurological or 
cognitive symptoms and less than 50 copies/ml in CSF and plasma.20 Subjects with 
CSF viral escape not meeting criteria for CSF/plasma discordance did not consistently 
have raised CSF mediator profiles. Such patients should also be considered for 
sensitive testing in plasma to determine the extent of discordance between the 2 
compartments. 
 
Some studies have demonstrated no association between CSF HIV RNA levels and 
cognitive performance.77 This may be due to the multifactorial nature of cognitive 
impairment in HIV rather than indicating that CSF HIV-1 detection does not have 
potential consequences for the brain.146 These data demonstrate that CSF/plasma 
discordance is associated with neuroinflammation and supports performing CSF HIV-
1 RNA quantification in clinical practice. In this study the majority of discordant 
subjects had plasma HIV-1 RNA levels that were unquantifiable on standard testing 
(median plasma HIV RNA <40 copies/ml, IQR <40,52) and would have been 
classified as successfully treated on plasma testing alone. No subject had plasma HIV-
1 RNA above 400 copies/ml, the level associated with long-term virological failure.89 
CSF discordance, even at low levels, should be investigated and treated; the 
indications for performing lumbar puncture solely to measure CSF HIV-1 RNA, and 
strategies for managing those patients found to be discordant, remain an important 
topic for future research.146 
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7 Identification of a prognostic model of clinical features 
and cerebrospinal fluid and plasma biomarkers for HIV 
associated neurocognitive impairment   
 
7.1 Introduction 
A number of clinical and laboratory parameters, and biomarkers in CSF and plasma, 
have been associated with the occurrence of HAND. It is unclear whether these 
parameters herald on-going damage and the progression of cognitive impairment over 
time.  
 
Tools to identify those at risk of developing HAND are required clinically to 
determine those patients that would benefit from more intensive monitoring of 
cognitive function and/or changes in antiretroviral therapy (ART) targeted at the 
CNS. Such tools could also be of use as endpoints in clinical trials characterising the 
effectiveness of ART in the CNS.  
 
7.2 Aims 
To assess the association of plasma/CSF biomarkers and clinical/laboratory 
parameters with changes in neurocognitive function over time in the CNS HIV Anti-
Retroviral Therapy Effects Research (CHARTER) cohort. 
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7.3 Methods 
I performed a focused analysis of the combined biomarker data arising from the 
CHARTER study. 
 
7.3.1 Patients 
The US National Institute of Mental Health-funded CHARTER cross-sectional cohort 
study recruited 1555 HIV-seropositive patients. Subjects were drawn from 6 
participating university centers: Johns Hopkins University (Baltimore, MD); Mt. Sinai 
School of Medicine (New York, NY); University of California at San Diego (San 
Diego, CA); University of Texas Medical Branch (Galveston, TX); University of 
Washington (Seattle, WA); and Washington University (St. Louis, MO). Subject 
recruitment began in September 2003 and ended in August 2007.  
 
The cohort was unselected and represented the clinic population at recruiting centres. 
The reported prevalence of cognitive impairment in this cohort was 53%.12  Subjects 
with ANI were at significantly higher risk of progressing to symptomatic or 
functional impairment than those with normal cognitive function.111 
 
7.3.2 Procedures 
All subjects completed a venipuncture, neuromedical assessment, comprehensive 
neuropsychological testing, detailed substance use history, structured psychiatric 
interviews for detecting lifetime and current diagnoses of substance use disorders and 
affective disorders, a measure of current mood, and self-reported assessments of 
cognitive symptoms, vocational functioning, and independence with instrumental 
activities of daily living. For details of testing procedures see the original CHARTER 
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publication.12 For those who consented (n=1,205), CSF was withdrawn by lumbar 
puncture. 
 
All participants completed a comprehensive neurocognitive test battery, covering 7 
cognitive domains known to be commonly affected by HIV-associated CNS 
dysfunction (administration time = 2–2.5 hours). The best available normative 
standards were used, which correct for effects of age, education, sex, and ethnicity, as 
appropriate. Test scores were automatically converted to demographically corrected 
standard scores (t scores) using available computer programs.  
 
7.3.3 Analysis 
Clinical features, including demographic and routine laboratory parameters, and a 
matrix of plasma and CSF biomarkers were compared with the subsequent change in 
neurocognitive function. Multiple linear regression analysis was employed with 
cognitive change score as the outcome variable. 
 
As many biomarkers have not been measured in the same patients at the same time-
point, multiple comparisons between biomarkers was not possible for the full data set. 
The following methods were employed to identify a matrix with the greatest number 
of biomarkers measured at the same time points in the same patients with the same 
duration of follow up. 
 
7.3.3.1 Biomarker selection 
Biomarkers with less than 20 measurements were excluded. In this analysis it was not 
possible to distinguish between biomarkers with undetectable levels due to assay 
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failure and those with levels truly falling below quantification threshold, therefore 
biomarkers  with skewed data due to a large proportion of the measurements falling 
below the lower limit of quantification were removed. The data was converted to a 
binary outcome (measured/not measured) and a hierarchical Euclidian cluster analysis 
(simple matching method), using the value of a measured time-point as the similarity 
metric, was performed in SPSS 22 to determine a matrix of biomarkers measured in 
the same patients at the same time-point. Overlapping clusters were then compared to 
determine the greatest number of biomarkers assessed at the greatest number of time 
points in the greatest number of patients.   
 
7.3.3.2 Time point selection 
Neurocognitive function was measured every 6 months for a variable duration up to a 
maximum of 8 years. As HAND develops slowly it was considered that follow up of 
less than 12 months is likely to reflect variation in testing rather than true 
neurocognitive decline.  To determine the most appropriate follow up period I 
calculated the number of biomarker measurements with neurocognitive data available 
at each time point after 12 months and selected the longest follow-up period for which 
the greatest proportion of the biomarker data remained available.  
 
7.4 Results 
7.4.1 Biomarkers 
Thirty-two CSF and 23 plasma biomarkers were measured a median of 206 times 
each (IQR 145,367). Seven-hundred and ninety subjects had at least one biomarker 
measured at at least one time point. Preliminary analyses were conducted to ensure no 
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violation of the assumptions of normality, linearity, multicollinearity and 
homoscedasticity. Ten biomarkers (9 CSF, 1 plasma) were removed due to skewed 
measurements. Ten biomarkers (7 CSF, 3 plasma) had less than 20 measurements and 
were also removed (CSF GM-CSF, IFN-g, IL-17, IL-4, MIP-1a, MIP-1B and 
RANTES; plasma GM-CSF, IL-4 and sCD163).  
 
Figure 12 demonstrates 5 clusters of biomarkers measured at similar time points 
(clusters 1-5). Clusters and individual biomarkers were examined to determine 
overlap and give the most extensive biomarker/patient matrix. Clusters 1 and 3 could 
be combined with biomarkers CSF IL1b, CD40L, IF10 and MCP1 to give 25 
biomarkers (10 CSF, 15 plasma) measured together 138 times in 138 subjects (ie. no 
more than 1 measurement per subject).  
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Figure 12. Euclidian hierarchical cluster analysis to determine biomarkers 
measured at common time points.  
Patient biomarker data converted to binary outcome (measured/not measured) 
underwent hierarchical Euclidian cluster analysis (simple matching method). This 
determined 5 clusters of biomarkers measured at similar time points (clusters 1-5). 
Overlapping clusters were then compared to determine the greatest number of 
biomarkers assessed at the greatest number of time points in the greatest number of 
patients.    
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7.4.2 Time-point selection 
Of subjects with the biomarkers measured in the clusters described above, 93 had 
neurocognitive data at 12 months follow-up. Extending the follow up period from 12 
to 18 months resulted in only 6% loss of measurements. Extending to 24, 30 and 36 
months resulted in much higher losses of 23%, 34% and 42% respectively (illustrated 
by changes in observations in total cohort over time in Figure 13). Based on this an 
18-month follow up was selected for analysis.  
 
 
 
 
 
Figure 13. Number of cognitive assessments (observations) performed at different 
lengths of follow up.  
Only subjects with at least one biomarker measured are included.    
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7.4.3 Patients  
Demographic and laboratory variables of the 88 subjects included in the model (ie. 
those with the clustered biomarkers measured and 18 month cognitive follow-up data 
available) are given in Table 18.  
	  
	  
Table 18. Demographic and laboratory variables in 88 patients selected for analysis 
All figures are at biomarker sampling. *1.7 = lower limit of quantification. ** CSF > 
0.5log10 plasma. 
Median (IQR) or n (%)
Age (years) 43 (39,49)
Gender Male 76 (86.4)
Education 13 (12,16)
White 48 (54.5)
Black 28 (31.8)
Hispanic 10 (11.4)
Other 2 (2.3)
145 (48,195)
AIDS diagnosis 56 (63.6)
Comorbidities
Incedental 62 (70.5)
Contributing 26 (29.5)
43 (48.9)
CD4 T-lymphocyte count (cells/mm3)
At sampling 428 (251,552)
Nadir 166 (43,284)
Log10 HIV-1 RNA
Plasma 2.6  (1.7,4.0)
CSF 1.7 (1.7,2.4)
HIV-1 RNA <LLQ*
Plasma 38 (43.2)
CSF 56 (63.6)
Discordant plasma/CSF HIV-1 RNA** 2 (2.3)
Antiretroviral therapy
NRTI 64 (72.7)
NNRTI 25 (28.4)
PI  41 (46.6)
Not on ART 22 (25.0)
CPE score 7 (6,8.75)
All figures are at biom rker samping
*1.7 = LLQ
** CSF > 0.5log10 plasma
Estimated duration of HIV 
infection (months)
Cognitive status impaired at 
baseline
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Variable Parameter  Univariate 
p value 
   
Comorbidities Clinical  0.36    
Age Clinical  0.798    
Education Clinical  *0.044    
Ethn1 Clinical  0.304    
Eth2 Clinical  *0.068    
Gender Clinical  *0.059    
AIDS status Clinical  0.975    
Est duration of 
inf 
Clinical  0.836    
CD4 Clinical  0.269    
Nadir CD4 Clinical  0.567    
Plasma HIV Clinical  0.76    
<LLQ plasma Clinical  0.482    
CSF HIV Clinical  0.968    
<LLQ CSF Clinical  0.862    
CSF-plasma 
HIV 
Clinical  0.672    
On ART Clinical  0.255    
CPE Clinical  0.107    
Cog impairment Clinical  0.233    
IGF-2 CSF  0.215    
IGFBP-1 CSF  0.749    
IGFBP-2 CSF  0.378    
IL-10 CSF  0.267    
IL-1b  CSF  0.179    
IL-6 CSF  0.24    
IP-10 CSF  0.219    
MCP-1 CSF  0.575    
sCD40L CSF  0.483    
TNFa CSF  *0.004    
IFNg Plasma  0.48    
IGF-1 Plasma  *0.008    
IGF-2 Plasma  *<0.0001    
IGFBP-1 Plasma  0.112    
IGFBP-2 Plasma  *0.073    
IL-10 Plasma  0.825    
IL-13 Plasma  0.115    
IL-17 Plasma  0.477    
IL-1b  Plasma  0.445    
IL-6 Plasma  0.881    
IP-10 Plasma  0.438    
MCP-1 Plasma  0.784    
MIP-1a Plasma  0.912    
sCD40L Plasma  0.485    
TNFa Plasma  0.801    
 
Table 19. Univariate regression of clinical features and plasma/CSF biomarkers 
compared with change in neurocognitive status at 18 months follow up.  
Star* indicates parameters taken forward into multivariate model. White, black or 
other ethnicity was transformed to binary outcomes; ethn1 and ethn2. Cog 
impairment is presence of HAND determined by Frascatti criteria.90  
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7.4.4 Linear regression 
The linear regression analysis was carried out in two stages. The first stage of the 
analysis was to investigate the association between each of the biomarkers 
independently and the change in cognitive score (Table 19). Those biomarkers shown 
to be significantly associated with change in cognitive score (p<0.1) were then taken 
forward to the multivariate analysis. From this initial analysis three clinical variables: 
education, ethnicity and gender were identified as being significantly related to 
change in cognitive score. Four biomarkers, CSF tumour necrosis factor alpha 
(TNFa), plasma insulin-like growth factor-1 (IGF-1), plasma insulin-like growth 
factor-2 (IGF-2) and insulin-like growth factor binding protein-2 (IGFBP-2) were also 
identified as being significantly related to change in cognitive score and were also 
carried forward for the multivariate analysis. The second stage of the analysis was to 
incorporate the seven clinical variables and biomarkers into a multivariate model. 
This was done using a forward stepwise process, adding one variable at a time, 
starting with the two with the smallest p values, into the model. A p value of 0.05 was 
used to determine statistical significance and a backward stepping approach with the 
same p value was used to test the consistency of the model. This stage of the analysis 
identified that the biomarkers plasma IGF-1 and IGF-2 were correlated with each 
other (Pearson’s r=0.664, p<0.0001) and were identifying the same proportion of the 
variability in the model. Effectively two similar models could be constructed 
containing either plasma IGF-1 or IGF-2 along with CSF TNFa. The first model is 
represented in Table 20 - r squared 0.230, p<0.0005.  
  
	   141	  
 
 
 
Standard error of 
the coefficient  
Unstandardised 
beta coefficient  p value 
Constant* 0.194 
 
0.001 
CSF TNFa 0.023 0.225 0.026 
Plasma IGF-2 <0.001** 0.374 <0.001 
 
Table 20. Results of multivariate linear regression of clinical factors and 
biomarkers against change in cognitive status at 18 month follow-up.   
*The value of the y intercept is -0.651.  
**The standard error of the coefficient for plasma IGF-2 is very low due to the scale 
of the variable,(ie the numerator (change in cognitive score) is small and, the 
denominator (plasma IGF-2) is relatively large) and the slope is not steep. 
 
 
In the second model plasma IGF-1 was substituted for IGF-2. The model remained 
significant but explained less of the variance in the outcome (r squared of 0.165, 
p=0.001). Both plasma IGF-1 and CSF TNFa made significant unique contributions 
to the model (p=0.010 and 0.005 respectively). Euclidian hierarchical cluster analysis 
of the 25 biomarkers in the model demonstrated a dominant closely related cluster of 
18 biomarkers (Figure 14). This was represented in the model by CSF TNFa. Both 
IGF1 and 2 were outside this cluster.  
  
	   142	  
 
 
Figure 14. Euclidian hierarchical cluster analysis of biomarkers in regression 
model. 
A dominant closely related cluster of 18 biomarkers was represented in the model by 
CSF TNFa   
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7.5 Discussion 
In this study, plasma IGF-1 and 2 and CSF TNFa had a protective effect on 
neurocognitive functioning over 18 months. The amount of the variance explained by 
the models may be insufficient for use clinically as prognostic indicators, however it 
is interesting that these biomarkers were able to predict cognitive change where 
standard clinical and laboratory parameters, in particular CSF/plasma HIV-1 RNA, 
were not.  
 
These findings were unexpected. Analysis of patients from the PARTITION study in 
chapter 6 demonstrated that higher concentrations of CSF mediators were associated 
with CSF/plasma discordance. Although detailed cognitive testing was not performed 
in PARTITION, it could be extrapolated that this would relate to more, rather than 
less, deterioration in neurocognitive functioning. Unfortunately these associations 
cannot be compared directly between the studies; IGFs were not measured in 
PARTITION and TNFa was excluded from analysis as levels were below the lower 
limit of quantification in over 80% of subjects. One explanation could be that 
CSF/plasma discordance was infrequent in the CHARTER cohort, occurring in less 
than 2% overall.12 Unlike in PARTITION, CSF biomarkers in the CHARTER cohort 
may not be reflecting ongoing replication of HIV in the CNS, but alternative 
protective mechanisms in those without discordance.  
 
IGFs have an important neuroprotective role in development, cell differentiation, 
plasticity, and neuronal survival/anti-apoptosis. They have been implicated in the 
pathogenesis of a number of neurodegenerative disorders.147 IGF treatment has been 
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shown to have neuroprotective and trophic effects in vitro and in vivo.148, 149 IGF-1 
and 2 have been shown to increase neuronal survival in HIV-1 infected brain cell 
cultures,150 and are protective in a murine model of HAND.151  
 
TNFa has a protective, as well as pro-inflammatory, role in the nervous system by 
diminishing the production of nitric oxide and free radicals, alteration of excitatory 
amino acid neurotransmission, maintenance of neuronal calcium homeostasis and 
induction of the synthesis of neurotrophic factors.152 Exposure to TNFa has been 
shown to render primary cortical neurons more resistant to excitotoxic cell death in 
vitro.153 The role of TNFa in HAND is unclear and TNFa has been implicated in both 
neuronal injury and neuronal protection in HIV-1 infected subjects.154 TNFa can 
enhance HIV-1 replication, but has also been shown to inhibit entry of HIV-1 into 
macrophages, the primary site of HIV-1 infection in the brain.155, 156  
 
7.6 Conclusion 
This analysis suggests a neuroprotective role for IGF-1 and 2 and TNFa in HIV 
infection. These biomarkers had greater predictive power for neurocognitive change 
than standard clinical and virological investigations. These cytokines require further 
investigation as prognostic indicators as well as potential therapeutic strategies for 
HAND. 	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8 Pharmacokinetics of Efavirenz and its major metabolites 
in cerebrospinal fluid, and relationship with CYP2B6 
c.516G>T genotype and perturbed blood brain barrier 
due to tuberculous meningitis 
 
8.1 Introduction 
Efavirenz (EFZ) is widely deployed within first-line combination HIV treatment 
regimens worldwide because of its superior effectiveness,157, 158  established safety 
record and resilience to rifampicin enzyme induction in patients who require 
concomitant anti-tuberculous therapy. EFZ undergoes rapid absorption, maximum 
plasma concentration is reached in 3–6 hours and therapeutic levels are reached 
within a few days of commencing treatment.159 However there is large interindividual 
variability in EFZ pharmacokinetics (PK),160-163 placing patients with low plasma 
concentrations at risk of losing virological control and developing resistance, or else 
developing adverse effects such as CNS toxicity.164, 165,10 EFZ is primarily 
metabolised by cytochrome P450 CYP2B6, to yield the most abundant metabolite 8-
hydroxy-efavirenz (8-OH-EFZ). Comparatively minor alternative metabolic pathways 
are through CYP2A6 (leading to the 7-OH-EFZ metabolite) and CYP3A,166 with most 
circulating metabolites (7-OH and 8-OH-EFZ) in plasma conjugated as glucuronides. 
 
EFV plasma concentrations relate strongly to genetic polymorphism in CYP2B6 
metabolism,167-171 including the most commonly studied CYP2B6 SNP c.516G>T 
(rs3745274), which encodes a Gln172His amino acid substitution. Clinical studies in 
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HIV-TB coinfected patients have consistently shown that these pharmacogenetic 
effects more than compensate for any reduction in EFV concentrations as a result of 
rifampicin enzyme induction, with some preliminary data suggesting that in CYP2B6 
poor metabolisers, CYP2A6 represents the dominant route of elimination and may be 
impacted by enzyme inhibition through concomitant isoniazid administration.172  
Furthermore, in-vitro experiments have reported that 8-OH-EFZ was associated with 
cytotoxicity via stimulation of mitochondrial dysfunction and stimulation of stress 
activated signaling pathways.173 Recently 8-OH-EFZ was shown to be neurotoxic in 
vitro at a concentration similar to those found in CSF.58 The role of 8-OH-EFZ in 
EFV-associated CNS toxicity has not been elucidated. 
 
8.2 Aims 
This study aimed to characterise the disposition of EFV and its metabolites within 
CSF in HIV-infected patients with and without tuberculous meningitis (TBM), and to 
evaluate the impact of phamacogenetic variability on drug disposition. 
 
8.3 Methods 
8.3.1 Participants and sampling 
Patients were recruited from Vietnam and the UK PARTITION study, referred to 
hereon in this chapter as studies A and B (not to be confused with groups A and B 
within the PARTITION study). 
 
Study A: In Vietnam, HIV-positive patients aged over 15 years with newly diagnosed 
TBM (ISRCTN63659091) were randomly assigned to receive immediate (within 7 
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days) vs. deferred (after 2 months) initiation of antiretroviral therapy as previously 
described.132, 133 EFZ was dosed at 800 mg if taken with rifampicin, or 600 mg if 
taken without rifampicin, together with zidovudine plus lamivudine in fixed-dose 
combination.  Anti-tuberculous therapy comprised isoniazid (5mg/kg/day; maximum 
300mg), rifampicin (10mg/kg/day; maximum 600mg), pyrazinamide (25mg/kg/day; 
maximum 2g), and ethambutol (20 mg/kg/day; maximum 1.2g) for 3 months followed 
by isoniazid plus rifampicin for 6 months. Unless contraindicated, all patients 
received dexamethasone as described elsewhere.174 Ethical approval was obtained 
from the Oxford Tropical Research Ethics Committee and the Hospital for Tropical 
Diseases Scientific and Ethical Committee.  
 
Study B: The UK based PARTITION study recruited subjects in 2 groups as 
described in section 3.1. All patients received 600mg of EFV once-daily.  
 
8.3.2 Efavirenz and metabolite measurement 
EFZ concentrations were determined in plasma and CSF samples taken from subjects 
receiving EFV at steady-state (>10 days)175 sampled at approximately mid-dosing 
interval. EFZ metabolite concentrations were determined in a single paired 
CSF/plasma sample per subject; measurements were repeated with and without beta-
glucuronidase and the ratio between albumin concentration in CSF and plasma/serum 
was determined. Genotyping was by real-time PCR, see section 3.3.5. 
 
8.3.3 Albumin ratio 
The ratio between albumin concentration in CSF and blood (plasma/serum) was 
determined by radial immunodiffusion (BindaridTM). Results are expressed in the 
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standard way using the units CSF albumin (mg/L) / blood albumin (g/L), hence the 
expressed ratio represents the true value x 103. CSF:blood albumin ratio indicative of 
a breach in integrity of the blood:brain barrier was taken as ≥6.8 for subjects less than 
45 years old and ≥10.2 for subjects over 45 years.176 
 
8.3.4 Neurotoxic concentrations 
Measured plasma and CSF concentrations were compared to the following 
concentrations associated with neurotoxicity: plasma EFZ concentrations greater than 
4000ng/mL associated with an increased risk of CNS side effects; plasma EFZ 
concentrations less than 1000ng/ml associated with virological failure;164 
concentrations of EFZ, 8OH-EFZ and 7OH-EFZ associated with dendritic spine 
damage in vitro: 100uM, 10uM and 100uM respectively.58 
 
8.4 Results 
8.4.1 Subjects 
Study A: EFZ and metabolite concentrations with and without b-glucuronidase were 
measured in paired plasma and CSF samples in 47 subjects. Sampling was mean 97 
days (95% CI 73-120) after commencing treatment. Mean age was 30 years and 
median CD4 at sampling was 88 cells/mm3. All were of Southeast Asian ethnicity.  
 
Study B: : EFZ and metabolite concentrations were measured in plasma and CSF in 
27 subjects. Mean age was 45 years and median CD4 at sampling was 432 cells/mm3. 
21 (78%) were of white ethnicity, 4 (15%) were of black ethnicity and 2 (7%) were of 
Asian ethnicity. CNS infection was excluded in 25 (93%) subjects; 1 subject had 
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cryptococcal meningitis and another had neurosyphilis. No subject was receiving 
antituberculous therapy or other enzyme inducing medication at the time of sampling.  
 
8.4.2 Efavirenz and metabolite concentrations in CSF and plasma with and 
without beta-glucuronidase 
Differences in the geometric mean concentration of EFZ and 8OH-EFZ in plasma 
were not significantly different between studies A and B. Concentrations of both EFZ 
and 8OH-EFZ in CSF were significantly higher in study A than B (both p<0.0001). 
(Figure 15). CSF:plasma ratio of EFZ concentration was median 2.7% [IQR 1.3,5.6] 
in study A and median 1.0% [IQR 0.7,1.2] in study B (p<0.0001). Plasma EFZ 
concentrations correlated with CSF EFZ concentration in both studies, but there was 
no correlation of plasma EFZ with CSF total 8OH-EFZ (Figure 16).  
 
 
 
 
Figure 15. Concentrations of efavirenz (a) and 8OH-efavirenz (b) in CSF and 
plasma between studies A and B.  
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[EFZ], efavirenz concentrarion; NS, not significant. 
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Figure 16. Relationship between plasma EFZ and CSF EFZ and 8OH-EFZ 
concentrations in studies A and B.   
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8OH-EFZ concentrations without b-glucuronidase were mean 87.3ng/mL (95% CI 
63.8-122.5) in plasma and 3.7ng/mL (95% CI 2.7-5.7) in CSF. 8OH-EFZ 
concentrations in were mean 6.4% (95% CI 4.3-9.5) of total in plasma, and 7.5% 
(95% CI 5.1-11.1) in CSF. Without b-glucuronidase, 7-OH-EFZ levels were below 
the lower limit of quantification in CSF and plasma. Concentrations of EFZ were not 
significantly changed by the addition on b-glucuronidase. Metabolite levels without b-
glucuronidase were too low for quantification in study B. 
 (Figure 17).  
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Figure 17. Study A; concentrations of EFZ, 8OH-EFZ and 7OH-EFZ in plasma 
(a) and CSF (b) with and without the addition of beta-glucuronidase. 
w/o, without enzyme; [EFZ], efavirenz concentration; [8OH-EFZ], 8-
hydroxyefavirenz concentration; [7OH-EFZ], 7-hydroxyefavirenz concentration; NS, 
not significant. 
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8.4.3 CYP2B6 genotype 
Forty-six samples in study A and 23 samples in study B were successfully genotyped 
for CYP2B6 c.516G>T (call rates 98% and 85% respectively). Allele frequencies are 
given in Table 21. CYP2B6 c.516G>T was in Hardy-Weinburg equilibrium in studies 
A and B (p=0.912 and 0.672 respectively). CYP2B6 c.516G>T genotype related to the 
concentration of EFZ in CSF and plasma in both studies A and B (Table 21). This 
relationship was also present in CSF for EFZ, but not for the concentrations of EFZ 
metabolites. There was no difference in CSF:plasma EFZ ratio according to genotype. 
The effect of CYP2B6 genotype on EFZ concentrations with respect to the estimated 
therapeutic range in plasma, and the in vitro toxic concentrations in CSF, are shown 
in Figure 19. 
 
Given the high linkage disequilibrium between the CYP2B6 c.516G>T functional 
polymorphism and other SNPs in the loci (Figure 18), it likely that this alone is the 
causal variant of the association with efavirenz concentrations and so haplotype 
analysis was not undertaken. 
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Table 21. CYP2B6 c.516G>T allele frequency and EFZ and metabolite 
concentrations in CSF and plasma in studies A and B.  
*p values are Chi squared (allele frequencies) or Mann Whitney U test between GG 
with GT/TT. 
Concentrations are median ng/ml (IQR) or n (%). All concentrations are with enzyme. 
NP – not performed; EFZ – efavirenz. w/o – without.  
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Figure 18. CYP2B6 linkage disequilibrium plot from 196 Vietnamese subjects 
(study A).  
 
  
	   157	  
	  
  
Figure 19. Effect of CYP2B6 c.516G.T genotype on estimated effective and toxic 
concentrations of efavirenz and total 8OH-EFZ concentrations in plasma and CSF.  
Plasma efavirenz levels in the estimated neurotoxic range were related to CYP2B6 
c.516G>T genotype (a and b). CSF EFZ above the in vitro toxic concentration was 
related to CYP2B6 c.516G>T genotype in study A (c), but not in study B where all but 
1 subject had CSF efavirenz concentrations below this level (d). CSF 8OH-EFZ 
concentrations (with beta-glucuronidase) were above the in vitro toxic concentration 
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in most subjects in both studies; this was not related to CYP2B6 c.516G>T genotype 
(c and f).  
MTC – minimum toxic concentration, MIC – minimum inhibitory concentration, ITC 
– in vitro toxic concentration. 
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8.4.4 CYP2A6 copy number variation 
Forty-six samples in study A were successfully genotyped for CYP2A6 copy number 
(call rate 98%). The CYP2A6 gene deletion occurred in 8 (17%) subjects and was in 
Hardy-Weinburg equilibrium (p=0.394). There was no association of CYP2A6 copy 
number with the concentration of EFZ or metabolites in plasma or CSF either singly 
or in combination with CYP2B6 genotype. A single subject had the CYP2A6 gene 
deletion in combination with homozygous CYP2B6 c.516G>T mutation; in this 
subject EFZ concentration was 6319.5 ng/ml in plasma and54.7 ng/ml in CSF. 
 
8.4.5 Albumin ratio 
CSF:serum/plasma albumin ratio was abnormal in 35 (90%) subjects in study A and 5 
(24%) in study B (p<0.0001). In study A CSF:plasma albumin ratio was positively 
correlated with the CSF:plasma ratio of EFZ (r=0.537, p<0.001) and total 8OH-EFZ 
(r=0.408, p=0.014). In study B CSF:serum albumin ratio had no significant 
correlation with the CSF:plasma ratio of EFZ or 8OH-EFZ. 
 
8.5 Discussion 
This is the first report of EFZ metabolites in CSF of patients with TBM and, to my 
knowledge, the first report describing concentrations of the 7OH-EFZ metabolite in 
CSF. These data demonstrate that the CYP2B6 c.516G>T polymorphism effects EFZ 
concentrations in CSF and well as plasma. 
 
EFZ metabolites may have entered the CNS by crossing the blood brain barrier, or 
resulted from the CNS metabolism of EFV. The majority of metabolites in CSF were 
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present as glucuronide conjugate. This may be due to CSF trapping of plasma 
glucuronidated compound, however the percentage free compound was not 
significantly higher in CSF than plasma. Alternatively EFV metabolites may be 
conjugated within the CNS. A number of UDP-glucuronosyltransferases have been 
demonstrated to be present in human brain tissue.177, 178 Functional CYP2B6 and 
CYP2A6 are present in the CNS and expression has been shown to be inducible and 
subject to genetic variation.179-181  
 
CSF concentrations of EFZ and metabolites were higher in those with loss of blood 
brain barrier integrity due to TBM infection. These differences in between Study A 
and B could not have been explained by the higher doses of EFV used in Study A 
(800mg vs 600mg), since plasma exposures were comparable across both studies. 
Concentrations were highest in TBM patients with the greatest loss of blood brain 
barrier integrity as measured by CSF:plasma albumin ratio. EFZ is >99.75% protein 
bound in blood.182, 183 Higher CSF EFZ concentrations may be due to leakage of free 
drug from plasma in those with loss of integrity of the blood brain barrier, or due to 
increased trapping of EFZ in those with higher albumin concentration in CSF.  
 
CSF EFZ concentrations consistently exceeded in vitro neurotoxic concentrations in 
patients with a combination of TBM infection and CYP2B6 c.516G>T mutation. In 
contrast CSF total 8OH-EFZ concentrations exceeded the in vitro neurotoxic 
concentration in the majority of subjects. Metabolite concentrations were independent 
of CYP2B6 c.516G>T genotype but were related to blood brain barrier integrity. This 
has implications for neuronal damage in TBM which could contribute to the overall 
	   161	  
neurological sequelae from this disease. The extent to which EFZ contributes to 
neurological sequelae in this situation is not known as any adverse neurological 
outcomes are likely to be attributed to TBM rather than drug neurotoxicity. 
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9 Effect of P-glycoprotein polymorphism on CSF 
darunavir concentration 	  
9.1 Introduction 
P-glycoprotein is a well charecterised ATP-dependent efflux pump with broad 
substrate specificity. P-plycoprotein is widely distributed and is expressed on brain 
capillary endothelium.184 The protease inhibitors, including darunavir, have been 
shown to be substrates for P-glycoprotein185 and it may be responsible for the low 
CSF levels observed in this class of ART.186  
 
P-glycoprotein is encoded by the ATP-binding cassette sub-family B member 1 
(ABCB1) gene. The ABCB1 c.3435T>A/C (rs1045642) SNP has been shown to 
correlate with P-glycoprotein expression and function.187, 188 ABCB1 c.3435T>A/C TT 
homozygotes have significantly decreased duodenal ABCB1 expression and increased 
P-glycoprotein substrate (digoxin) plasma concentrations.189 P-glycoprotein 
expression has also been correlated with a promoter SNP, T-129C, and the non-
synonomous SNP ABCB1 c.2677T>A/G (rs2032582), which results in an Ala→Ser 
amino acid change at position 893 of the protein. ABCB1 c.2677T>A/G has been 
shown to be in linkage disequilibrium with c.3435T>A/C.190, 191  
 
The hypothesis of this study was that functional ABCB1 single nucleotide 
polymorphisms would be associated with darunavir concentrations in CSF due to 
differences in the expression of P-glycoprotein on the blood brain barrier.  
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9.2 Aims 
To determine the effect of ABCB1 polymorphism and blood brain barrier permeability 
(as measured by CSF:serum albumin ratio) on the CSF:plasma DRV concentration 
ratio.  
 
9.3 Methods 
Paired CSF/plasma samples and genetic material were obtained from subjects in the 
PARTITION study (groups A and B). Drug assay and other methods are given in 
section 3.3.1.3.  
 
9.4 Results 
Paired plasma and CSF samples were analysed in 48 darunavir treated subjects.  
 
9.4.1 Demographic and clinical variables  
Median age was 48 years (IQR 43,55). 43 (90%) were male. 40 (83%) were white 
ethnicity, 8 (17%) were black. 36 (75%) were MSM risk group, 8 (17%) were 
heterosexual, 2 (4%) were intravenous drug users and in 2 (4%) the HIV acquisition 
risk was unknown.  Adherence was ≥95% in 43 (90%) subjects. All subjects were 
taking darunavir, other antiretroviral drugs at sampling were: NRTI 38 (79%), NNRTI 
4 (8%), raltegravir 6 (13%), maraviroc 2 (4%).  
 
9.4.2 Indication for lumbar puncture 
16 (33%) were from recruitment group B. Within group A the indications for lumbar 
puncture were as follows: to investigate cognitive symptoms (n=14), headache (n=4), 
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to investigate abnormal neurological examination (n=4), enrolled in PIVOT CSF 
substudy (n=2), follow up progressive multifocal leucoencephalopathy (n=1), to 
measure JC viral DNA (n=1), seizure (n=1), to measure CSF HIV RNA (n=1), 
possible neurosyphilis (n=1), acute confusion (n=1), suspected CMV encephalitis 
(n=1), suspected multiple sclerosis (n=1) and sepsis unknown source (n=1). Based on 
lumbar puncture results CNS infection was suspected in 3 (6%) subjects, although no 
pathogen was identified. One subject had probable viral radiculopathy, 1 had raised 
CSF opening pressure (40cm/H2O) and 1 had CSF pleocytosis (13 cells/ul) of 
unknown cause.  
 
9.4.3 Genotype analysis 
ABCB1 c.3435T>A/C (rs1045642) and ABCB1 c.2677T>A/G (rs2032582) 
polymorphisms were in linkage disequilibrium; D’=0.871.  
 
No significant associations were found between CSF:plasma darunavir concentration 
and ABCB1 SNPs, either singly or in combination (Table 22 and 23). No significant 
differences were observed in multivariate analysis including time post dose (Figures 
20 and 21). 
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Table 22. Association of the ABCB1 c.3435T>A/C polymorphism with CSF and 
plasma darunavir concentration. 
	  	  
 
 
Figure 20. Darunavir concentration in plasma (filled symbols) and CSF (open 
symbols).  
Darunavir concentrations in CSF and plasma were not associated with ABCB1 
c.3435T>A/C (rs1045642) polymorphism in a multivariate model including time post 
dose.  
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Table 23. Association of the ABCB1 c.2677T>A/G polymorphism with CSF and 
plasma darunavir concentration 
	  
 
 
	  
Figure 21. Darunavir concentration in plasma (filled symbols) and CSF (open 
symbols)  
Darunavir concentrations in CSF and plasma were not associated with ABCB1 
c.2677T>A/G (rs2032582) polymorphism in a multivariate model including time post 
dose. 
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9.4.4 CSF:serum albumin ratio 
CSF:serum albumin ratio was measured in 23 subjects (48%). Median CSF:serum 
albumin ratio (expressed as mg/L:g/L) was 7.1 (IQR 5.3,8.4). CSF:serum albumin 
ratio was not correlated with CSF:plasma darunavir concentration (r=0.025, p=0.900); 
Figure 22. 	  	  	  	  
 
Figure 22. No significant correlation was found between CSF:serum albumin ratio 
(expressed as mg/L:g/L)  and CSF:plasma darunavir concentration. 
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9.5 Discussion 
There was considerable inter-individual variability in CSF darunavir concentrations, 
as has been previously observed.192  In part this variability relates to random 
sampling. The variability was not related to differences in blood brain barrier 
permeability as measured by CSF:serum albumin ratio. This implies that active 
transport via brain endothelium influx/efflux transporters may be responsible for the 
significant observed inter-individual variation in CSF darunavir concentrations. In 
this study however, polymorphism of the measured ABCB1 SNPs did not account for 
this variation.  
 
The measured SNPs did not alter P-glycoprotein expression on the blood brain barrier 
to sufficient degree to cause observable changes in CSF darunavir concentration. 
ABCB1 c.3435T>A/C has been shown to be the functional SNP in most, but not all 
tissues; for example in placenta the c.2677T>A/G SNP was more important.190, 191 It 
may be that another SNP is functional in the expression of P-glycoprotein in brain 
endothelium.  Alternatively, influx/efflux via membrane transporters other than P-
glycoprotein may have a role. PIs have been shown to be substrates for other multi-
drug resistance-associated protein (MRP) transporters and breast cancer resistance 
protein (BCRP),193 and darunavir transport via organic anion transporting polypeptide 
(OATP) 1A2 and -1B1 has been reported.194 
 
Kim et al. demonstrated dramatic (7-40 fold) increases in brain tissue concentrations 
of four different protease inhibitors in an ABCB1 knockout mouse.55 This difference 
was much greater in brain than for any other tissue (plasma, heart, lung, liver, spleen, 
kidney, small intestine, colon). Whether CSF darunavir levels measured in this study 
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reflected brain tissue levels is unclear. The blood brain barrier and blood CSF barrier 
differ in drug transporter expression, although P-glycoprotein is expressed on both.195  
 
Several other factors effect P-glcoprotein expression, in particular induction and 
inhibition due to a number of drugs including many antiretroviral drugs 
coadministered with darunavir.196 In addition P-glycoprotein expression on brain 
endothelium, astrocytes and microglia has also been shown to be affected by CNS 
inflammation in HIV and correlates with the histopathological degree of HIV-
encephalitis.197 Whether these factors were important in this cohort is not clear from 
these data.  
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10 General discussion 
10.1 Overview 
A review article based on the introduction chapter to this thesis was published in The 
Lancet Neurology.198 It is the first major review article to directly address the 
controversies that have divided the field and suggest approaches to resolving key 
issues of debate. Its publication represents an important output from this thesis. 
 
The significance of findings from this thesis are discussed in the individual chapter 
discussions. Below describes how overlapping aims and complimentary findings from 
the different chapters address the hypotheses laid out in chapter 2.  
 
10.1.1 CSF/plasma discordance is a common determinant of viral detection in 
plasma 
The PARTITION data suggest that lumbar puncture should be performed in subjects 
with incomplete viral suppression in plasma to measure CSF viral load and determine 
resistance profiles of HIV in the CSF. There is currently no consensus amongst 
clinicians as to whether this is appropriate management, and no guidance on the 
subject from professional bodies such as BHIVA or EACS. These data provide the 
first direct evidence upon which to inform this decision. Data presented in chapter 5 
demonstrate that CSF/plasma discordance is a not uncommon occurrence in subjects 
with incomplete viral suppression in plasma, occurring in 18% of the cohort. This is a 
novel finding and PARTITION is the first study to address this issue. Data in chapter 
4 shows that discordance is associated with history of immune suppression, 
suggesting the presence of HIV in the CNS relates to a longer duration of viral 
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replication and more advanced immune suppression. CSF resistance data presented in 
chapter 4 demonstrate that HIV resistance mutations can be identified from the CSF 
in patients with viral detection at levels too low for genotypic resistance testing in 
plasma. These findings have potential management implications for a large number of 
patients. Unexplained viral detection in plasma ≥50 copies/ml is a common clinical 
problem; in one study 122 (27%) of 448 subjects developed plasma blips ≥50 
copies/ml over a median of 485 days. An additional 19 (4%) had persistent low-level 
viraemia between 50 and 400 copies/ml.199 Given the large number of HIV infected 
individuals currently receiving ART,2 this problem is likely to affect several thousand 
patients in the UK. I aim to prospectively assess the impact of providing lumbar 
puncture in this situation in a follow-up study - see section 10.2.2 below. 
 
10.1.2 Biomarkers of neuroinflammation are associated with CSF/plasma 
discordance and neurocognitive impairment 
Chapter 6 shows that CSF/plasma discordance is associated with raised expression of 
CSF biomarkers, suggesting potentially damaging CNS inflammatory processes in 
this group. Unexpectedly, data presented in chapter 7 found levels of TNFa and 
IGF1/2 were protective from deterioration in cognitive function. The significance of 
this is unclear. Despite the large number of biomarkers analysed, very few had 
significant associations with cognitive change. The model overall was poorly 
predictive and certainly not a clinically useful tool. One explanation for the apparently 
discrepant findings from chapters 6 and 7 is that CSF/plasma discordance was 
uncommon in the CHARTER cohort, described in just 2% of the population overall.12 
This implies that the progressive cognitive change may be due to causes other than 
ongoing HIV replication in the CNS and the potentially damaging neuroinflammatory 
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response shown in chapter 6 may not be an important factor here. As described in 
section 1.5.1, subjects in the CHARTER cohort had a large number of comorbidities 
which were linked to cognitive status. Comorbid conditions contributing to the 
observed cognitive decline may have limited the ability to detect an association with 
measured mediator concentrations.  
 
Another important finding from this thesis is that an appropriate definition for 
CSF/plasma discordance should be >0.5log10. This is based on CSF resistance 
demonstrated in subjects with low discordance in chapter 4, and raised CSF mediator 
profiles in this group in chapter 6. Subjects with 0.5-1log10 discordance, or 
discordance but <200 copies/ml in CSF, should not be excluded, as has been the case 
in some studies.8, 68 This is important for future studies in this area as use of this lower 
cut off reduces the risk of type 2 error.  This finding is also important clinically as it 
guides management decisions in patients with CSF/plasma discordance detected at 
levels of previously uncertain significance. In addition the field should move away 
from using CSF escape when this does not meet the 0.5log10 level of discordance. 
Although used in many studies as well as in clinical practice, this criterion is prone to 
overestimate the extent of the problem. The definition of CSF viral escape (≥40 
copies/ml in CSF and <40 copies/ml in plasma) would theoretically include a subject 
with 41 copies/ml in CSF and 39 copies/ml in plasma; such differences are likely to 
represent random biological and statistical variation or limitations of the assay, rather 
than CNS compartmentalised virus.89 Of note, CSF viral escape has not been 
associated with cognitive impairment in large cross sectional studies.12, 200 This may 
represent a situation where sensitive HIV RNA testing is appropriate to determine the 
true degree of CSF/plasma discordance; ie patients with CSF viral escape at levels not 
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meeting criteria for CSF/plasma discordance could be considered for sensitive testing 
in plasma to determine the true extent of discordance between the two compartments.  
 
10.1.3 Low CSF antiretroviral drug concentrations are an important 
determinant of ART failure in the CNS and lead to CSF/plasma 
discordance and resistance  
Although assays to measure CSF antiretroviral drug concentrations remain a research 
tool, requests are sometimes made by clinicians to perform CSF drug levels for 
individual patients and this practice may become more widespread with time. It is 
important to determine which patients are likely to benefit from CSF drug level 
testing, and in which clinical situations this is appropriate. Interestingly, data from 
chapters 4 and 5 do not support that antiretroviral drug concentrations in CSF are 
associated with ongoing replication of HIV within the CNS. This may in part be due 
to the random sampling and inability to accurately model Cmin for most drugs. This 
may also be due to differences between the concentration of drugs in the CSF and that 
within perivascular macrophages, a critical target cell of HIV in the brain.4	  Chapter 8 
suggests that 8-hydroxy-efavirenz could be measured in CSF to assess neurotoxicity 
mediated by efavirenz metabolites. However as the majority of 8-hydroxy-efavirenz 
measurements were in the potentially neurotoxic range this may not be useful 
clinically. Data presented in chapters 4 and 5 show no association of CSF/plasma 
discordance with CPE score, however no firm conclusions can be drawn from this as 
the PARTITION study was not designed to assess the CPE score, was not 
randomised, and is prone to type 2 error due to prescriber bias (ie the demonstrated 
tendency for clinicians to prescribe regimens with a high CPE score to patients with 
CNS problems).114 
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10.1.4 Pharmacogenetic factors such as CYP2B6 and ABCB1 genotype impact 
the distribution of antiretroviral drugs into the CSF 
Chapter 8 shows that CYP2B6 genotype is an important determinant of plasma and 
CSF concentrations of efavirenz. CYP2B6 was not associated with the neurotoxic 
metabolite 8-hydroxy-efavirenz concentrations in CSF. CSF 8-hydroxy-efavirenz 
concentrations were also independent of plasma efavirenz concentrations suggesting 
that neither genotyping nor therapeutic drug monitoring would be helpful in 
protecting patients from the harmful effects of efavirenz in the CNS.  Chapter 9 found 
no association of ABCB1 polymorphism with darunavir concentrations in CSF. 
Together these chapters do not support genotyping to predict CSF concentrations, 
however there are several limitations to this analysis including that the subjects were 
randomly sampled and the data not modeled to predict Cmin. More work could be 
done in this area to further elucidate these mechanisms and the potential impact of 
pharmacogenetics on antiretroviral distribution in the CNS. However, chapters 4 and 
5 show that CSF drug concentrations may not be a useful marker of ART efficacy in 
the CNS and hence CSF drug levels may not be the outcome of interest. I understand 
that investigators from the CHARTER study are planning to undertake a genome 
wide association study, looking at cognitive change as well as CSF drug 
concentrations. The results of this will be interesting, but may be limited by the 
effects of comorbidities on cognitive function, as discussed above.  
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The following outlines two areas of future study arising directly from this work. The 
first project has already been funded as part of an MRC Early Career Award, awarded 
in January 2014. Phylogentic analysis is currently underway at Centers for Disease 
Control and Prevention (CDC) in Atlanta. The second project takes forward findings 
from the PARTITION study; it is anticipated this will form part of an Intermediate 
Fellowship application.  
 
10.2 Further research leading on from this work 
10.2.1 Characterising viral divergence in PARTITION  
The observation of the relationship between residual HIV-1 RNA detection in plasma 
and HIV-1 RNA levels in the CSF supports the hypothesis that the CNS serves as a 
site of on-going HIV replication during ART, and that CSF/plasma discordance can 
lead to persistence of HIV-1 RNA in plasma. To address this hypothesis and extend 
my current observations, I will characterise the HIV quasispecies in plasma and CSF 
of the subjects identified, using clonal analysis and next generation sequencing, 
followed by phylogenetic analysis to determine the genetic relatedness of viral strains. 
By sensitive sequencing methodologies, I will also determine whether HIV-1 RNA 
detection in the CNS is associated with the emergence of HIV resistance to the 
components of the ART regimen, and will assess the correlation between any drug 
resistant strain detected in the CSF and the drug susceptibility profile of plasma 
strains.  
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This work will addresses important clinical questions: Why is ART unable to 
eradicate HIV infection? Does HIV continue to replicate during seemingly successful 
ART? What is the site of the on-going HIV replication?  Does it account for the 
detection of residual HIV-1 RNA in plasma? With this study I aim to provide 
conclusive evidence to support the hypothesis that HIV-1 replication continues in the 
CNS despite plasma HIV-1 RNA load suppression below the target level proposed by 
current guidelines (50 copies/ml), and that such replication causes residual HIV-1 
RNA persistence in plasma.  
 
10.2.2 PARTITION 2; the effect of treating CSF/plasma discordance on viral 
persistence in plasma  
The PARTITION study demonstrated that CSF/plasma discordance is a frequent 
finding in subjects with incomplete viral suppression in plasma (ie. ≥50 copies/ml), 
however the current data do not conclusively show this association to be causal, or 
that treating viral persistence in CSF will improve viral detection in plasma. In the 
PARTITION 2 study I propose to charecterise a cohort of patients with incomplete 
HIV RNA suppression in plasma and follow them longitudinally for 2 years. Lumbar 
puncture will be performed at enrollment. In cases where CSF/plasma discordance is 
identified, antiretroviral treatment will be modified with respect to the genotypic 
resistance profile in CSF. If no resistance is identified in CSF, treatment will be 
adjusted according to estimated distribution into the CNS. Subjects identified to have 
CSF/plasma discordance will have a further lumbar puncture 6 months after treatment 
change, and thereafter every 6 months until CSF HIV-1 RNA is no longer discordant 
(using the <0.5log10 cutoff). Subjects without CSF/plasma discordance at enrollment 
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will be followed over the same period with sensitive plasma HIV RNA monitoring to 
act as a comparator group. Adherence to antiretroviral treatment will be closely 
monitored with pill counting and Medication Event Monitoring System (MEMS).  
 
This project aims to conclusively answer the following important clinical questions: 
Should lumbar puncture be considered in all subjects with unexplained HIV RNA 
persistence in plasma? Does targeted treatment based on the CNS (ie. CSF resistance 
and/or estimated CNS penetration) lead to decreased HIV RNA in CSF in those with 
CSF/plasma discordance? Does treating CSF virus decrease viral detection in plasma? 
I intend to develop this proposal as part of an Intermediate Fellowship application.  
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Appendix 
Publications arising from this thesis 	  
Nightingale S, Winston A, Letendre S, Michael BD, McArthur J, Khoo S, Solomon T. 
Controversies in HIV-associated Neurocognitive Disorders. Review article. Lancet 
Neurology 2014 Nov;13(11):1139-1151.  
 
Pozniak A, Rackstraw S, Deayton J, Barber T, Taylor S, Manji H, Melvin D, Croston 
M, Nightingale S, Kulasegaram R, Pitkanen M, Winston A. HIV associated 
neurocognitive disease: case studies and suggestions for diagnosis and management in 
different patient sub-groups. Antiviral Therapy 2014;19(1):1-13. 
 
Nightingale S, Michael BD, Defrees S, Benjamin LA, Solomon S. Test them all; an 
easily diagnosed and readily treatable cause of dementia with life threatening 
consequences if missed. Editorial. Practical Neurology 2013 Dec;13(6):354-6.  
 
Nightingale S, Geretti AM, Nelson M, et al. HIV-1 RNA detection in cerebrospinal 
fluid in those on antiretroviral therapy experiencing incomplete viral suppression in 
plasma; the PARTITION study. In preparation 
 
Nightingale S, Chau	  T, Fisher M, et al. Pharmacokinetics of efavirenz and its major 
metabolites in CSF of HIV-infected patients; influence of CYP2B6 G516T genotype 
and perturbed blood brain barrier due to tuberculous meningitis. In preparation 
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Nightingale S, Michael BD, Ustianowski A, et al. CSF/plasma HIV-1 RNA 
discordance above 0.5log10 associated with raised expression of CSF mediators 
compared with non-discordant subjects. In preparation 
 
Key presentations 	  
Nightingale S, on behalf of the PARTITION investigators. HIV-1 RNA Detection in 
CSF in ART Treated Subjects with Incomplete Viral Suppression in Plasma. 
Conference for Retrovirology and Opportunistic infection (CROI) 2014, Boston 
Massachusetts. 	  
Nightingale S. The CNS has an HIV reservoir (the PARTITION study). 18th Annual 
Resistance and Antiviral Therapy Meeting, Royal College of Physicians, London. 
September 2014.  
 
Nightingale S, Khoo S, Pirmohammed M, Solomon T. HIV and the Brain; Results 
from the PARTITION Study. Malawi-Liverpool-Wellcome Conference. Malawi. 
September 2013. 
 
Nightingale S, Solomon T. Penetration of Antiretroviral Therapy into the Nervous 
System; Cognitive Impairment in HIV and the Role of the CNS as a Sanctuary Site. A 
Progress Report on the PARTITION Study. Poster presentation at Association of 
British Neurologists Annual Conference May 2012.  Abstract in J Neurol 
Neurosurg Psychiatry 2012;83:Suppl 2 
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